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Abstract 
Blood shortages are serious problems worldwide, and demand for blood for transfusion 
therapy is only expected to increase. In Japan, the Red Cross Society estimates that 
approximately 850,000 people will face medical challenges due to blood shortages each year 
by 2027. The development of an artificial O2-carrier as a red blood cell (RBC) substitute is 
widely considered an optimal solution. In the last few decades, several types of hemoglobin 
(Hb)-based O2-carriers (HBOCs) have been developed, but none have been approved for 
transfusion therapy because the side effects, including vasoconstriction and increased blood 
pressure, cannot be avoided. 
Recently, we synthesized core-shell protein clusters comprising a bovine (HbBv) or 
human adult hemoglobin (HbA) in the center and human serum albumins (HSAs) at the 
periphery. This Hb–HSA3 cluster, named “HemoAct,” is a promising RBC substitute and O2 
therapeutic reagent. The Hb–HSA3 cluster has a large molecular weight (264 kDa) and a 
strong negative net surface charge (pI: 5.0), which may prove effective in preventing 
hypertensive action with extravasation and prolonging blood-circulation persistence. To 
evaluate the safety and efficacy of the Hb–HSA3 cluster in preclinical and clinical tests, 
enlargement of the preparation scale and simplification of the procedure are required. 
In this thesis, the author presents an improved preparation procedure for HbBv–HSA3 
clusters with O2-binding ability comparable to those of clusters synthesized by conventional 
procedures. Second, the author establishes an expression system of recombinant HbA (rHbA) 
using Pichia pastoris by genetic engineering, and prepared rHbA–rHSA3 clusters as an 
entirely synthetic O2-carrier. Furthermore, an rHbA(X)–rHSA3 cluster variant with an O2 
affinity similar to that of human RBCs is prepared by site-direct mutagenesis in the heme 
pocket of the core rHbA. 
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Chapter 1 
 
General Introduction  
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1.1 Structure and Function of Hemoglobin 
Hemoglobin (Hb) is a tetrameric O2-transporting hemoprotein composed of two α- and 
β-globins (α2β2). Each globin has iron(II)-protoporphyrin IX (Mw: 616.49, Figure 1-1) as a 
prosthetic heme group.1–3 In the case of human adult Hb (HbA), the molecular weight is 
approximately 64,500 Da (including 4 hemes) and the number of amino acid residues is 141 
for α-globin (15,126 Da) and 146 for β-globin (15,867 Da), respectively. These globins have 7 
(α-globin) or 8 (β-globin) α-helices designated A to H from the N-terminus, but α-globin lacks 
the D helix (Figure 1-1).4 The heme is located in the cavity between the F helix (proximal 
side) and the E helix (distal side) known as the “heme pocket.” The heme iron has 6 
coordination bonds. Four are occupied by pyrrole nitrogens of heme, the fifth site is bound to 
a proximal histidine (F8 His: α58, β63) in the globin, and the sixth makes a complex with 
gaseous molecules such as dioxygen (O2), carbon monoxide (CO), and nitric monoxide (NO). 
 
 
Figure 1-1. Structure of heme and oxy HbA (Protein Data Bank ID: 2DN1): α-globin (red) and β-globin 
(pink). 
 
Since the X-ray crystal structure horse Hb was reported by Perutz et al. in 1960,5,6 the 
relationship between three-dimensional (3-D) structure and O2-binding ability has been 
clarified. The tertiary structures of each globin of Hb and myoglobin (Mb) are almost 
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identical, although the O2-equilibrium curves differ. Mb produces a rectangular hyperbolic 
curve, but Hb displays a characteristic sigmoidal curve (Figure 1-2A). The quaternary 
structural transition of Hb between the relaxed (R) state (high O2 affinity) and the tense (T) 
state (low O2 affinity) (Figure 1-2B) can be attributed to cooperativity, which is induced by 
ligand binding and enhanced by an allosteric effector such as 2,3-bisphosphoglycerate 
(2,3-BPG) and inositol hexaphosphate (IHP). Arnone first reported the 2,3-BPG binding site 
on HbA.7 Richard et al. and Xia et al. reported a detailed location, which is surrounded by 
His-β2, Lys-β82, (Asn-β139), and His-β143.8,9 
 
Figure 1-2. (A) O2-dissociation curves of HbA at several CO2 pressures (solid line: PCO2 = 0 Torr pH 7.4; 
dot-dot line: 0 Torr pH 7.2; and dashed line: 40 Torr pH 7.2) at 37 °C.2 (B) Superimposed structure of the 
oxy HbA (R-state) (α-globin: red, β-globin: pink; Protein Data Bank [PDB] ID: 2DN1) and deoxy HbA 
(T-state) (α-globin: blue, β-globin: pale green; PDB ID: 2DN2). 
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Two monumental descriptions of the cooperativity of Hb have been proposed; stepwise 
dioxygenation and a two-state allosteric model.10,11 The stepwise model proposed by Adair in 
1925 presumed that O2-binding to Hb is a 4-step sequential reaction that does not distinguish 
between the reactivity of α- and β-globins. In comparison, the 2-state Monod–Wyman–
Changeux (MWC) model proposed by Monod et al., assumed a 2-state equilibrium between 
the T and R states with different O2 affinities. We can obtain the O2-binding parameters of Hb 
by analyzing the O2-dissociation curve. The O2 affinity of Hb is commonly expressed as a P50 
value, which means the O2 partial pressure at which 50% of Hb is dioxygenated. 
Cooperativity is expressed by an n value, the Hill coefficient, which can be calculated from 
the Hill equation: 
Y =
(𝑃O2 𝑃50⁄ )
𝑛
1 + (𝑃O2 𝑃50⁄ )
𝑛
 
log
𝑌
1−𝑌
= 𝑛 log (
𝑃O2
𝑃50
) = 𝑛 log 𝑃O2 − 𝑛 log 𝑃50, 
where Y is the O2 saturation of Hb, PO2 is O2 partial pressure, and n is the Hill coefficient. In 
fact, O2-dissociation curve fitting can be performed as a function of Adair’s theory or MWC 
models.12,13 
Adair’s model can be expressed by: 
Y =
𝑎1𝑃O2 + 2𝑎2𝑃O2
2 + 3𝑎3𝑃O2
3 + 4𝑎4𝑃O2
4
4(1 + 𝑎1𝑃O2 + 𝑎2𝑃O2
2 + 𝑎3𝑃O2
3 + 𝑎4𝑃O2
4)
 
where Y is O2 saturation of Hb, PO2 is O2 partial pressure, and ai (i = 1–4) is a constant 
composed of the intrinsic Adair association constants: a1 = 4 k1, a2 = 6 k1 k2, a1 = 4 k1 k2 k3, 
and a1 = k1 k2 k3 k4. 
The MWC model can be expressed as: 
Y =
𝐿𝑐𝛼(1 + 𝑐𝛼)3 + 𝛼(1 + 𝛼)3
𝐿(1 + 𝑐𝛼)4 + (1 + 𝛼)4
 
where L is an allosteric constant, c is the ratio of intrinsic association constant (= KT/KR), and 
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α is the O2 activity, including the KR (= KR PO2). The O2-binging properties (P50, n) of human 
Hb (HbA) and bovine Hb (HbBv) are summarized in Table 1-1.14–20 
 
Table 1-1. O2-binding properties of HbA and HbBv in several conditions 
Buffer condition 
HbA HbBv 
P50 (Torr) n (–) P50 (Torr) n (–) 
10 mM HEPES (pH 7.2), [Cl] = 0 at 37 °Ca 4.4 2.2 12.8 2.7 
50 mM bis-Tris (pH 7.2), [Cl] = 0.1 M at 37 °Ca 11.5 2.8 26.4 2.7 
100 mM PB (pH 7.4) at 37 °Cc 15 2.5 29 2.1 
PBS (pH 7.4) at 37 °C 14.4d/12e 2.8d/2.4e 23f 2.6f 
Hemox buffer (pH 7.4) at 37 °C 12e/13.5g 2.4e/2.6g – – 
50 mM bis-Tris (pH 7.2), [Cl] = 0.1 M at 25 °Ca 5.4 2.7 14.5 3.0 
50 mM bis-Tris (pH 7.4), [Cl] = 0.1 M at 25 °Cb 5.3 3.02 16.7 2.98 
a Ref. 14, b ref. 15, c ref. 16 (only HbBv added 0.1 M NaCl), d ref. 17, e ref. 18, f ref. 19, g ref. 20. 
 
1.2 Development of a Red Blood Cell Substitute as an Artificial O2-Carrier 
The development of an artificial O2-carrier as an RBC substitute is attracting attention 
because of serious concern regarding blood shortages associated with declining birth rates and 
aging populations. The ideal artificial O2-carrier has a long preservation period and no blood 
type, so it could be transfused to anyone at any time without cross-matching.21–23 RBC 
products cannot be treated (heat sterilization or filtration) for virus inactivation, while an 
artificial O2-carrier poses no risk of infection by, for example, hepatitis or human 
immunodeficiency virus.24 
Artificial O2-carriers can be divided into two categories: (i) perfluorocarbon (PFC)-based 
O2-carriers, and (ii) Hb-based O2-carriers (HBOCs) (Table 1-2). Liquid PFC is colorless and 
insoluble in water, and must be emulsified before transfused. The PFC emulsion formulation 
Fluosol (Green Cross Corp., Japan) was the first and only product to be approved in the US 
(in 1989) and European countries as an O2 therapeutic reagent, but it was withdrawn in 
11 
 
1994.23,25–27 HBOCs can be further subdivided into cellular types: also called 
liposome-encapsulated Hb, which is a liposome composed of a phospholipid filled with Hb,28–
30 and acellular types: chemically modified Hb with intramolecular31–34 or intermolecular 
cross-linking,35–38 or biocompatible polymers conjugation, such as polyethylene-glycol 
(PEG),17,39–41 oligosaccharides,20,42–45 and proteins.18,46–49 Currently, development of artificial 
O2-carriers is dominated by HBOCs because of their high O2-transporting efficacy and 
biocompatibility. Stroma-free (unmodified) Hb transfused in the bloodstream dissociates to an 
αβ dimer and is rapidly eliminated through the spleen, kidney, and liver.21 Intramolecularly 
cross-linked Hb, which is designed to avoid dimer dissociation, has been tested. However, it 
produced an unfavorable increase in blood pressure by vasoconstriction because nitric oxide 
(NO) was scavenged by Hb released from blood vessels. To avoid these problems, several 
groups have developed polymerized Hbs and PEGylated Hbs to increase molecular size and 
circulation lifetimes. Unfortunately, none has reached practical use.50,51 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
T
a
b
le
 1
-2
. 
L
is
t 
o
f 
re
p
re
se
n
ta
ti
v
e 
ar
ti
fi
ci
al
 O
2
-c
ar
ri
er
s 
R
ef
. 
2
5
, 
2
6
 
2
5
, 
2
7
 
  2
2
, 
3
1
 
2
2
, 
3
2
 
2
2
, 
3
8
 
2
2
 
2
2
 
D
ev
el
o
p
er
 
G
re
en
 C
ro
ss
 C
o
rp
.,
 J
ap
an
 
A
ll
ia
n
ce
 P
h
ar
m
. 
C
o
rp
.,
 U
S
 
  B
ax
te
r,
 U
S
 
S
o
m
at
o
g
en
, 
In
c.
, 
U
S
 
B
io
p
u
re
 C
o
rp
.,
 U
S
 
B
io
p
u
re
 C
o
rp
.,
 U
S
 
N
o
rt
h
fi
el
d
 L
ab
.,
 U
S
 
M
aj
o
r 
co
m
p
o
n
en
t 
P
er
fl
u
o
ro
d
ec
al
in
, 
p
er
fl
u
o
ro
 t
ri
p
ro
p
y
la
m
in
e 
P
er
fl
u
o
ro
-o
ct
y
l 
b
ro
m
id
e 
  H
b
A
, 
D
B
B
F
 
R
ec
o
m
b
in
an
t 
H
b
A
(d
i-
α
) 
H
b
B
v,
 g
lu
ta
ra
ld
eh
y
d
e 
H
b
A
, 
g
lu
ta
ra
ld
eh
y
d
e 
H
b
A
, 
g
lu
ta
ra
ld
eh
y
d
e 
P
ro
d
u
ct
 n
am
e 
F
lu
o
so
l®
 
O
x
y
g
en
t™
 
  H
em
A
ss
is
t™
 
O
p
tr
o
™
 (
rH
b
1
.1
) 
H
em
o
p
u
re
®
 
(H
B
O
C
-2
0
1
, 
H
b
 g
lu
ta
m
er
-2
5
0
) 
O
x
y
g
lo
b
in
®
 
(H
B
O
C
-3
0
1
) 
P
o
ly
H
em
e™
 
C
at
eg
o
ry
 
P
er
fl
u
o
ro
ca
rb
o
n
 
(P
F
C
) 
  H
b
-b
as
ed
 O
2
-c
ar
ri
er
 
(H
B
O
C
) 
C
ro
ss
-l
in
k
ed
 H
b
 
 P
o
ly
m
er
iz
ed
 H
b
 
  
 
13 
 
T
a
b
le
 1
-2
. 
L
is
t 
o
f 
re
p
re
se
n
ta
ti
v
e 
ar
ti
fi
ci
al
 O
2
-c
ar
ri
er
s 
R
ef
. 
3
9
 
1
7
, 
4
0
 
2
0
, 
4
3
 
4
6
 
1
8
, 
4
8
 
 2
8
, 
3
0
 
2
9
, 
3
0
 
A
b
b
re
vi
a
ti
o
n
; 
D
B
B
F
: 
3
,5
-d
ib
ro
m
o
sa
li
cy
l-
b
is
-f
u
m
al
at
e,
 M
al
: 
m
al
ei
m
id
e 
g
ro
u
p
, 
S
O
D
: 
su
p
er
o
x
id
e 
d
is
m
u
ta
se
, 
C
A
T
: 
ca
ta
la
se
, 
D
P
P
C
: 
d
ip
al
m
it
o
y
l 
p
h
o
sp
h
at
id
y
lc
h
o
li
n
e,
 D
P
P
G
: 
d
ip
al
m
it
o
y
l 
p
h
o
sp
h
at
id
y
lg
ly
ce
ro
l,
 D
P
E
A
: 
d
ip
al
m
it
o
y
l 
L
-g
lu
ta
m
at
e-
N
-s
u
cc
in
ic
 a
ci
d
. 
D
ev
el
o
p
er
 
S
an
g
ar
t,
 I
n
c.
, 
U
S
 
M
an
ju
la
 a
n
d
 A
ch
ar
y
a 
et
 a
l.
, 
U
S
 
H
em
o
so
l 
In
c.
, 
C
an
ad
a 
D
’A
g
n
il
lo
 a
n
d
 C
h
an
g
 e
t 
a
l.
, 
U
S
 
K
o
m
at
su
 e
t 
a
l.
, 
Ja
p
an
 
 B
u
rn
et
te
 e
t 
a
l.
, 
U
S
 
T
su
ch
id
a 
an
d
 S
ak
ai
 e
t 
a
l.
, 
Ja
p
an
 
M
aj
o
r 
co
m
p
o
n
en
t 
H
b
A
, 
im
in
o
th
io
la
n
e,
 
M
al
-P
E
G
5
k
 
H
b
A
, 
im
in
o
th
io
la
n
e,
 
M
al
-P
E
G
5
k
 
H
b
A
, 
g
lu
ta
ra
ld
eh
y
d
e,
 
ra
ff
in
o
se
 
H
b
B
v,
 C
A
T
 (
b
o
v
in
e)
, 
S
O
D
 (
b
o
v
in
e)
, 
g
lu
ta
ra
ld
eh
y
d
e,
 p
y
ri
d
o
x
al
-p
h
o
sp
h
at
e 
H
b
 (
b
o
v
in
e 
o
r 
h
u
m
an
),
 
H
S
A
 
 H
b
A
, 
ch
o
le
st
er
o
l,
 D
P
P
C
, 
D
P
P
G
 
H
b
A
, 
ch
o
le
st
er
o
l,
 D
P
P
C
, 
D
P
P
G
, 
P
E
G
5
k
-D
P
E
A
 
P
ro
d
u
ct
 n
am
e 
H
em
o
sp
an
®
 
(M
P
4
) 
P
E
G
-H
b
 
H
em
o
li
n
k
™
 
(o
-R
af
fi
n
o
se
 p
o
ly
H
b
) 
P
o
ly
H
b
-S
O
D
-C
A
T
 
H
em
o
A
ct
™
 (
H
b
–
H
S
A
3
) 
 N
eo
h
em
o
cy
te
 
H
b
V
 (
H
b
-v
es
ic
le
s)
 
C
at
eg
o
ry
 
P
E
G
y
la
te
d
 H
b
 
 C
o
n
ju
g
at
ed
 H
b
 
   L
ip
o
so
m
e-
en
ca
p
su
la
te
d
 H
b
 
 
14 
 
1.2.1 Cross-Linked Hb 
Diaspirin Cross-Linked Hb (DCLHb) “HemAssist” 
The diaspirin cross-linked HbA (DCLHb), which is cross-linked between Lys-α99 in HbA by 
bis(3,5-dibromosalycil) fumarate (DBBF) in an N2 atmosphere and the presence of 2,3-BPG, 
was reported by Walder et al. in 1986.31 The DCLHb shows a high O2 affinity (P50 = 27 Torr 
at 37 °C, pH 7.4) and Hill coefficient (n = 2.7).34 The DCLHb produced by Baxter Corp. 
(USA) was named “HemAssist.” Hb concentration of the formulation is 10 g/dL.52 DCLHb is 
one of the first-generation HBOCs to be evaluated in preclinical and clinical tests. However, 
in phase III trials, DCLHb was associated with significantly higher mortality rates compared 
with control groups,52 possibly due to hypertension by NO scavenging and organ injury by 
free-radical generation.34 
 
1.2.2 Polymerized Hb 
Polymerized HbBv “Hemopure” 
Biopure Corp. (USA) developed glutaraldehyde polymerized HbBv, which consists of 
intermolecular cross-linked HbBv with glutaraldehyde with a relatively large molecular 
weight of 130–500 kDa.51 The product name is “Hemopure”34 The P50 value (38 Torr) was 
higher than that of human RBCs (25 Torr). The Hb concentration of the formulation in 
modified Ringer’s lactate was 13 g/dL. The tetrameric and polymeric HbBv contents were 
determined by size-exclusion chromatography (SEC); tetrameric content was less than 1% 
and polymeric (> 500 kDa) content was approximately 10%.53 Hemopure can be stored in a 
deoxy form at room temperature for at least 3 years.38 The product was approved for human 
use in South Africa in 2001. Hemopure advanced phase III clinical trials in the US, but it has 
not been approved by the US Food and Drug Administration because of concerns regarding 
vasoconstriction.38 
15 
 
Polymerized HbA “PolyHeme” 
Northfield Lab. (USA) developed pyridoxalated and polymerized HbA, which is cross-linked 
by glutaraldehyde and pyridoxal 5’-phosphate (PLP) with a molecular weight of 130–250 
kDa.24,51 The product, known as “PolyHeme,”34 had a P50 value (28–30 Torr) slightly higher 
than that of human RBCs and a moderate Hill coefficient (n = 1.7). Hb concentration of the 
formulation in a physiological electrolyte solution was 10 g/dL. The monomeric HbA content 
was less than 1%. The product showed no serious adverse effects in phase I and II studies. 
However, trials of PolyHeme were suspended because there was no significant improvement 
in 30-days mortality, and more adverse events in the group.54 
 
1.2.3 PEGylated Hb 
PEGylated HbA (MP4) “Hemospan” 
Maleimide-PEG (Mal-PEG)-conjugated HbA (MP4), which is prepared by Mal-PEG5k and 
thiolated HbA by 2-iminothiolane, was reported by Winslow et al. in 2003.39 The molecular 
weight of MP4 as determined by SEC was approximately 95 kDa, with a PEG-binding 
number of approximately 6. The O2-binding parameters (P50, n) are 6 Torr and 1.2 in PBS at 
37 °C. MP4 was produced by Sangart Inc. (USA) with a formulation name of “Hemospan.” 
The formulation has high O2 affinity and colloid osmotic pressure (COP; 55 mmHg) and a 
low Hb concentration (4.3 g/dL).24 Hemospan showed non-hypertensive action in clinical 
experiments. However, only transient elevations were observed in typical liver function 
markers such as aspartate aminotransferase, alanine aminotransferase, and lactate 
dehydrogenase.55 Phase III clinical trials in orthopedic surgery patients were carried out in 
Europe, but revealed no significant improvement in adverse events compared with a control.56  
16 
 
 
 
 
 
 
Chapter 2 
 
Synthesis of Hemoglobin–Albumin Clusters  
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2.1 Introduction 
In 2013, our laboratory (Komatsu et al.) first reported a core-shell structured-protein cluster 
comprising HbBv wrapped covalently with HSAs — an HbBv–HSA3 cluster.48 Similar 
protein clusters using HbA were synthesized in 201518 in a formulation named “HemoAct.” 
Hb–HSA3 clusters feature a high molecular weight (264 kDa) and negative net surface charge 
(pI 5.0). The cluster achieved long blood-circulation lifetimes and produced no side effects 
such as increased blood pressure and cardiac toxicity in animal experiments.57,58 
Evaluations of the safety and efficacy of HbBv–HSA3 and HbA–HSA3 cluster 
formulations in preclinical and clinical tests require enlarged preparation scales and 
establishment of a simple purification system. Earlier reported procedures suffered from two 
drawbacks: (i) water solubility of the cross-linker was low, and (ii) scale-up of purification 
method was difficult. The cross-linker, N-succinimidyl 4-(maleimidemethyl) 
cyclohexane-1-carboxylate (SMCC), would not dissolve in water above 1.6 mM because it 
had a hydrophobic cyclohexane spacer. We therefore used a more soluble cross-linker. The Hb 
concentration in the reaction can be increased and the synthesis efficiency improved. 
Meanwhile the purification method used gel-filtration chromatography (GFC), which limits 
the maximum separable volume at one time. Generally, a loading sample volume of less than 
5 vol% of the gel volume is recommended,59 which is an impediment to large-scale 
purification. As a result, we tried to isolate HbBv–HSA3 clusters from the reaction mixture 
using anion exchange chromatography (AEC). 
 
2.2 Structure and Function of Human Serum Albumin 
HSA is a globular protein with a molecular weight of 66,438 Da, and no prosthetic group or 
glycosylation.60 It consists of 585 amino acid residues, including 35 cysteine (Cys) residues, 
34 residues of which form disulfide bonds (17 pairs), which contributes to the stabilization of 
18 
 
the tertiary structure of HSA. The remaining Cys (Cys-34) is unpaired and has a free 
sulfhydryl (-SH) group. HSA consists of three homologous domains: I (loops 1–3), II (loops 
4–6), and III (loops 7–9) (Figure 2-1). Each domain is categorized by subdomain A and B 
from the N-terminus: loops 1–2, IA; loops 4–5, IIA (drug-binding site I); loops 7–8, IIIA (site 
II); loop 3, IB; loop 6, IIB; and loop 9, IIIB, respectively. 
 
Figure 2-1. Structure of HSA (PDB ID: 1E78) and enlarged view around Cys-34. The color indicates each 
subdomain; blue: IA, light blue: IB, green: IIA, palegreen: IIB, red: IIIA, pink: IIIB, respectively. 
 
An expression system for recombinant HSA (rHSA) has been established in various 
species such as Escherichia coli,61,62 Saccharomyces cerevisiae,63 and Pichia pastoris.64 An 
rHSA formulation as the drug excipient “Recombumin” (Albumedix Ltd.) was approved by 
the US Food and Drug Administration and by agencies in other countries. Some rHSA 
formulated as blood expanders are in clinical trials. In addition, HSA exhibits superior 
retention in the bloodstream, because its strong negative net surface charge (pI: 4.9) inhibits 
glomerular filtration and blood vessel permeation. Chemical and genetic conjugation with 
HSA has therefore been commonly used to prolong the blood-circulation lifetime of drugs and 
therapeutic proteins.65–69 
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2.3 Synthesis of Hemoglobin–Albumin Clusters 
2.3.1 Preparation of Highly Purified Hemoglobin from Bovine Blood 
A method for preparing highly purified HbBv has been reported previously,48 but we 
improved the procedure. Using tangential flow filtration (TFF) to remove RBC membranes 
allowed us to purify 2 liters of bovine blood, which is equivalent to a 100-fold increase in 
volume compared with the previous method. SDS-PAGE showed two bands and native-PAGE 
showed a single band (Figure 2-2). The HbBv concentration was measured using the 
extinction coefficient of cyano-met Hb assay (ε541 = 4.4 × 104 M−1 cm–1).70 The HbBv yield 
was 52% from washed RBC (wRBC). 
 
Figure 2-2. (A) SDS-PAGE and (B) native-PAGE patterns of HbBv. 
 
2.3.2 Synthesis of Hemoglobin–Albumin Clusters 
Komatsu et al. previously reported synthesizing core-shell structured-protein clusters 
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comprising an Hb in the center and HSA at the periphery in the form of Hb–HSA3 
clusters.18,48 The conventional cross-linker N-succinimidyl 4-(maleimidomethyl) 
cyclohexane-1-carboxylate (SMCC) shows low solubility in water. We employed 
N-succinimidyl 3-maleimidopropionate (SMP, Figure 2-3A) with a high water solubility to 
achieve the reaction at a high HbBv concentration.19 
 
 
Figure 2-3. (A) A synthetic scheme of the HbBv–HSA3 cluster using the SMP cross-linker and AEC 
purification. (B) Isolation of individual components of the HbBv–HSA3 cluster by GFC. 
 
SMP was reacted with carbonyl HbBv to yield maleimide-activated HbBv (MA-HbBv). 
To avoid autoxidation of the hemes in HbBv during the reaction process, carbonyl HbBv was 
used as a raw material. Subsequently, the maleimide terminals of MA-HbBv were coupled 
site-specifically with a free sulfhydryl group (Cys-34) of HSA. A cluster formation was 
confirmed using SEC. Multiple peaks based on the HbBv–HSAm cluster appeared in the 
chromatogram of the resulting reaction mixture (retention time 13–18 min, Figure 2-4). The 
unreacted free MA-HbBv was not detected (retention time 20.3 min), indicating complete 
reaction of MA-HbBv to the cluster. 
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Figure 2-4. SEC profiles of the resulting reaction mixture (MA-HbBv + HSA). 
 
The SMP was soluble in phosphate-buffered saline (PBS) solution containing 9% 
dimethyl sulfoxide (DMSO) at 13.6 mM, but SMCC did not dissolve at the same 
concentration. Consequently, the coupling reaction was conducted in 1 mM of HbBv, which is 
a concentration 10 time that used in the conventional method. The spacer length (5.9 Å) of 
SMP is short (SMCC: 8.3 Å), and we anticipated that reactivity of Hb would decline. 
Nevertheless, the cluster was obtained in a condition with 15-fold excess moles of SMP to 
HbBv, which is 75% of the previously reported amount using SMCC (20-fold moles).48 Using 
a similar cross-linking agent, N-succinimidyl 4-maleimidobutanoate (SMB), under the same 
conditions as SMP also yielded a cluster. However, SMB is more expensive that SMP, which 
is one of the more affordable α-maleimide-ω-succinimide cross-linking agents. 
 
2.3.3 Experimental Section 
Preparation of Highly Purified Hemoglobin from Bovine Blood 
Bovine blood was purchased from Tokyo Sibaura Zouki Co. Ltd. Sodium citrate was used as 
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an anticoagulant. First, the bovine blood in 750 mL bottles (total 2 L, [HbBv] = 12 g/dL) was 
centrifuged (1,000 g at 4 ºC) for 30 min. After removing the plasma component, an equivalent 
volume of saline solution (Otsuka Pharmaceutical Co., Ltd.) was added and the mixture was 
centrifuged. This cycle was performed 3 times to obtain wRBC ([HbBv] = 4.2 mM, 0.65 L). 
The same volume of deionized water (0.65 L) was then added to the wRBC and incubated for 
overnight at 4 ºC for hemolysis. The suspended solution in 750 mL bottles was centrifuged 
(4,415 g at 4 ºC) for 45 min to precipitate the insoluble RBC membrane components. The 
obtained red supernatant was filtered through 100 μm and 45 μm stainless-steel sieves. The 
solution was then filtered through two TFF modules (Pellicon 2 Mini Cassette; Durapore 2 
0.22 μm, Biomax 2 300 kDa molecular weight cutoff [MWCO]) using a TFF system (flow 
rate: 150 mL/min) to remove RBC membrane debris, yielding 1.8 L of HbBv solution. Finally, 
sufficient carbon monoxide (CO) gas was flowed to prepare carbonyl HbBv. A portion of the 
solution (0.6 L) in a 1 L round-bottomed flask was heated at 70 ºC for 4 h on a dry aluminum 
block with stirrer (Tokyo Rikakikai Co., Ltd.), with gentle stirring in a CO atmosphere in the 
dark to exclude remaining plasma proteins. After centrifugation (4,415 g at 4 ºC) for 20 min, 
the obtained supernatant was dialyzed against deionized water using a membrane tube (6–8 
kDa MWCO), followed by the addition of 5.3% (1/19) volume of 20× PBS, yielding 1.4 L of 
HbBv ([HbBv] = 1.1 mM). 
 
Synthesis of Hemoglobin–Albumin (HbBv–HSA3) Clusters 
A freshly prepared DMSO solution of SMP (150 mM, 9.6 mL) was added dropwise to a PBS 
solution (10 mM phosphate, 137 mM NaCl, pH 7.4) of carbonyl HbBv (1 mM, 96 mL) in a 
300 mL round-bottom flask. The mixture was stirred for 90 min in a CO atmosphere at 4 °C. 
After removing the unreacted excess SMP with a GFC column (Sephadex G-25 superfine; GE 
Healthcare UK Ltd.) using PBS as running buffer, the volume of the MA-HbBv was adjusted 
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to 288 mL ([HbBv]= 0.33 mM) by adding PBS. Then, 25% HSA (3.76 mM, 153.2 mL) was 
diluted by a unique phosphate buffer (PB; 38.8 mL, 58.3 mM sodium phosphate, 435.7 mM 
NaCl, 13.4 mM KCl, pH 7.2). The PBS solution of HSA (3 mM, 192 mL) was added 
gradually to the MA-HbBv. Subsequently, the reaction mixture (total 480 mL) was stirred for 
72 h in a CO atmosphere in the dark at 4 °C. An HbBv–HSA3 cluster formation was 
confirmed using SEC on a high-performance liquid chromatography (HPLC) system 
(Prominence LC-20AD/CTO-20A/SPD-20A; Shimadzu Corp.) with an SEC column 
(YMC-Pack Diol-300 S-5; YMC Co. Ltd.) using a 50 mM PB (pH 7.4) as the mobile phase. 
The SMP was reacted with surface Lys residues on HbBv. The maleimide terminals of 
MA-HbBv coupled site-specifically with a free sulfhydryl group (Cys-34) of HSA, yielding 
the HbBv–HSA3 cluster. 
 
2.4 Purification of a Hemoglobin–Albumin Cluster using Anion Exchange 
Chromatography 
2.4.1 Purification of the HbBv–HSA3 Cluster using AEC 
In the previously describe method, we separated the HbBv–HSA3 clusters and unreacted HSA 
from reaction mixture using GFC (Superdex 200pg. column).18,48 Although, GFC is a 
common separation procedure, it suffers from two shortcomings when scaled up. First, the 
separation efficiency depends strongly on the sample injection volume, and second, each 
fractionated sample needs to be analyzed to confirm the existence of the target molecules. To 
overcome these difficulties, we attempted to use AEC, which has been applied widely at 
industrial scales.19 
Negatively charged proteins bind strongly to the positively charged AEC gel (Q 
Sepharose Fast Flow). They are eluted by decreasing the pH and/or increasing the ionic 
strength of the running buffer. Separating the HbBv–HSA3 cluster and HSA with very close 
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isoelectric points (pI) using AEC appeared to be difficult, but an HbBv–HSA3 cluster and 
HSA are separable only by changing the NaCl concentration of the running buffer. This 
improved effect is probably attributable to the large surface area of the cluster molecules, 
which provides multipoint interactions with the cationic gel surface and engenders stronger 
adsorption compared with HSA. 
The HbBv–HSA3 cluster is a mixture of four components with different binding numbers 
of HSA without unreacted HSA (SEC retention time = 18.7 min, Figure 2-5A). The average 
number of HSAs per Hb core was ascertained from [total protein]/[HbBv unit] assays to be 
3.0 ± 0.2 (mean ± standard deviation [SD]), which is identical to the value of the HbBv–HSA3 
cluster prepared using SMCC.48 The obtained cluster is denoted as HbBv–HSA3 (with an 
italicized subscript 3). The circular dichroism (CD) spectrum of the HbBv–HSA3 cluster 
coincided with the sum of the HbBv spectrum and a 3-fold enlarged HSA spectrum (Figure 
2-5B). From the 480 mL reaction mixture, the obtained solution volume was 74 ± 6 mL (yield 
60 ± 4%, mean ± SD, n = 5, Figure 2-6). The metHb content of the cluster was only 3 ± 1%. 
 
 
 
 
 
 
 
 
 
Figure 2-5. (A) SEC profiles of the reaction mixture and HbBv–HSA3 cluster after AEC separation and (B) 
CD spectra of HbBv–HSA3 cluster, HbBv ([HbBv unit] = 0.2 μM), and HSA (0.2 μM) at 25 ºC. 
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Figure 2-6. HbBv–HSA3 cluster solution ([HbBv unit] = 5 g/dL in PBS) in 100 mL-bottle. 
 
2.4.2 Isolation of Individual Components of HbBv–HSA3 Clusters 
Native-PAGE of the HbBv–HSA3 cluster also revealed four bands with different migration 
distances (Figure 2-7A). Each component was isolated carefully by GFC using a Superdex 
200 pg column (Figure 2-3B, Figure 2-7). The eluent fractions showing a single band in 
native-PAGE were collected (Figure 2-7A). Each component was checked again using SEC 
measurements (Figure 2-7B). On the basis of the protein and Hb assay, the HSA/Hb ratios of 
each component appearing at 15.0, 15.5, 16.2, and 17.5 min in the SEC curve were 
ascertained to be 4.0, 3.0, 2.0, and 1.0, respectively (Figure 2-7B). From [total protein]/[HbBv 
unit] assays, native-PAGE, and CD spectroscopy, we identified the individual components as 
the HbBv–HSA4 heteropentamer, HbBv–HSA3 heterotetramer, HbBv–HSA2 heterotrimer, and 
HbBv–HSA1 heterodimer (Figure 2-7).  
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Figure 2-7. (A) Native-PAGE and (B) SEC profiles of HSA, HbBv, HbBv–HSA3 cluster, and its 
component (50 mM PB, pH 7.4), and (C) their CD spectra ([HbBv unit] = 0.2 μM) at 25 ºC. 
 
The isoelectric points of all the clusters (pI: 5.0) were markedly lower than that of naked 
HbBv (pI: 7.0), and nearly identical to the value of HSA (pI: 4.9), indicating that the surface 
charge is independent of HSA number (Figure 2-8). Binding of a single HSA to Hb is 
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sufficient to reduce the net surface charge to pI 5.0, because HSA is a strong acidic protein. 
Dynamic light scattering (DLS) measurements demonstrated that the hydrodynamic 
diameters of the clusters increased markedly in proportion to the number of the HSA moiety 
(Table 2-1). 
 
 
 
 
 
 
 
 
 
 
Figure 2-8. IEF patterns of the HbBv–HSA3 and its components. 
 
Table 2-1. Average binding numbers of HSA, isoelectric points, and diameters of the 
HbBv–HSA3 and its components 
Hemoprotein HSA/HbBv ratio (mol/mol) pI (–) Diameter (nm) 
HbBv – 7.0 6.4 
HSA – 4.9 8.2 
HbBv–HSA3 3.0 (average) 5.0 14.4 
HbBv–HSA1 1.0 5.0 9.5 
HbBv–HSA2 2.0 5.0 11.4 
HbBv–HSA3 3.0 5.0 13.0 
HbBv–HSA4 4.0 5.0 14.8 
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2.4.3 Experimental Section 
Purification of HbBv–HSA3 Clusters using AEC 
The reactant (240 mL) of MA-HbBv and HSA was subjected to AEC with a Q Sepharose Fast 
Flow (500 mL; GE Healthcare UK Ltd.) in a glass chromatography column (5 cm internal 
diameter, 50 cm length) using PBS as running buffer. After flushing with a 10 mM PB (167 
mM NaCl, pH 7.4, five-column volume) to wash out the excess HSA, HbBv–HSA3 was 
eluted with a 10 mM PB (297 mM NaCl, pH 7.4). The eluent was then dialyzed against 
deionized water at 4 °C using a TFF system (Pellicon XL Ultrafiltration Module Biomax 30 
kDa; Millipore Corp.), followed by the addition of 5.3% volume of 20× PBS. Finally, the 
HbBv–HSA3 was concentrated ([HbBv unit] = 5 g/dL) using centrifugal ultrafilters (Amicon 
Ultra 15, 10 kDa MWCO; Merck Millipore Ltd.). The total protein concentration and HbBv 
concentration were measured using a protein assay kit (Pierce 660 nm; Thermo Fisher 
Scientific Inc.) and the extinction coefficient of cyano-metHb (ε541 = 4.4 × 104 M–1 cm–1). 
 
Isolation of Individual Components of HbBv–HSA3 Clusters 
The resultant HbBv–HSA3 cluster was subjected to GFC on a fast protein liquid 
chromatography (FPLC) system (Äkta Prime Plus; GE Healthcare UK Ltd.) with a Superdex 
200 pg (HiLoad 26/60; GE Healthcare UK Ltd.) column using a 50 mM PB (pH 7.4) as 
running buffer. The eluent was monitored at 280 nm and each component was carefully 
isolated. Fractions showing a single band in native-PAGE were collected. Each component 
was checked again using SEC measurements. 
Native-PAGE was performed using 5–15% poly(acrylamide) precast gel (SuperSep Ace 
5–15%; Fujifilm Wako Pure Chemical Corp.). Isoelectric focusing (IEF) was conducted using 
a pH 3–10 IEF gel (Novex pH 3–10; Thermo Fisher Scientific Inc.). CD spectra were 
obtained at 25 ºC using a CD spectrometer (J-820; Jasco Corp.). DLS measurements were 
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conducted using a zeta potential and particle-size analyzer (ELSZ-2000ZS; Otsuka 
Electronics Co., Ltd.) in a PBS solution (pH 7.4) with a protein concentration of 10 μM at 25 
ºC. 
 
2.5 O2-Binding Property of Hemoglobin–Albumin Cluster 
2.5.1 O2-Binding Property of Hemoglobin–Albumin Cluster 
The visible absorption spectral patterns of HbBv–HSA3 clusters and native HbBv in a PBS 
solution (pH 7.4) under N2, O2, and CO atmospheres (deoxy, oxy, carbonyl forms) were 
fundamentally equivalent to those of naked HbBv, suggesting that the coordination structures 
and electronic states of the hemes are identical (Figure 2-9, Table2-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-9. Visible absorption spectral changes of the HbBv–HSA3 cluster in PBS solution (pH 7.4) at 25 
ºC. 
Table 2-2. Visible absorption spectral data of HbBv and HbBv–HSA3 
clusters in PBS solution (pH 7.4) at 25 ºC 
Hemoprotein 
λmax (nm) 
oxy deoxy carbonyl 
HbBv 414, 541, 577 430, 555 420, 538, 569 
HbBv–HSA3 414, 541, 577 430, 556 420, 538, 569 
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The P50 and n value of the HbBv–HSA3 cluster were 9 Torr and 1.4, respectively (Figure 
2-10, Table 2-3). These values show moderately high O2 affinity compared with naked HbBv 
(P50 = 23 Torr, n = 2.6). Individual cluster components showed the same P50 and n values. No 
clear dependence on the HSA binding number was observed in the O2-binding parameters. We 
inferred two structural reasons for high O2 affinity of the HbBv–HSA3 cluster. The first 
involved the masking of a sulfhydryl group of Cys-β93 in HbBv by the maleimide terminus of 
SMP. Blocking of Cys-β93 is known to attenuate the quaternary structure motion of Hb and 
enhance O2 affinity.71–73 This result is consistent with the findings reported by Rosa et al. and 
Acharya et al. that chemical modification of Cys-β93 of HbA reduces P50 and n values.71,72 
The second reason is the modification of surface Lys residues of Hb by the succinimide 
terminal of SMP. Palmer et al. and Winslow et al. demonstrated that HBOCs in which the 
surface Lys residues were chemically modified possess markedly higher O2 affinity than that 
of naked Hb.39,74 The MA-HbBv showed the same O2 affinity (P50 = 9 Torr, n = 1.4) as the 
HbBv–HSA3 cluster. We inferred that chemical modification of SMP interfered with the 
transformation of the relaxed (R)-state conformation (oxy and carbonyl forms) of the Hb core 
to the tense (T)-state conformation (deoxy form) with low O2 affinity. 
 
 
 
 
 
 
 
 
 
Table 2-3. O2-binding parameters of HbBv–HSA3 cluster and its 
components in PBS solution (pH 7.4) at 37 ºC 
Hemoprotein P50 (Torr) n (–) 
HbBv 23 2.6 
HbBv–HSA3 9 1.4 
HbBv–HSA1 9 1.5 
HbBv–HSA2 9 1.4 
HbBv–HSA3 9 1.4 
HbBv–HSA4 9 1.4 
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Figure 2-10. O2-dissociation curves of HbBv and HbBv–HSA3 clusters in PBS solution (pH 7.4) at 37 ºC. 
 
2.5.2 Experimental Section 
The visible absorption spectra of HbBv and HbBv–HSA3 clusters ([HbBv unit] = 3 μM) were 
measured in carbonyl, oxy, and deoxy forms. To prepare the oxy form, carbonyl Hb in a PBS 
solution (pH 7.4) was irradiated using a 50 W LED lamp while O2 gas flowed through. The 
oxy Hb in a PBS solution was deoxygenated in an N2 atmosphere by adding 20 μM sodium 
dithionite. HbBv–HSA3 clusters were prepared with the identical procedure. 
The O2 affinity (P50: O2 partial pressure, where the Hb is 50% saturated) and the Hill 
coefficient (n) were determined using an automatic recording system for the O2-dissociation 
curve (Hemox Analyzer; TCS Scientific Corp.) in PBS (pH 7.4) at 37 ºC ([HbBv unit] = 10 
μM). 
 
2.6 Chromogenic LAL Assay of LPS in Hemoglobin–Albumin Cluster 
2.6.1 Chromogenic LAL Assay of LPS in Hemoglobin–Albumin Cluster 
Bacterial endotoxin lipopolysaccharide (LPS) derived from the exterior cell membrane of 
Gram-negative bacteria is universally contaminated by trace amounts in distilled water and all 
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aqueous solutions in the laboratory.75 LPS causes pyrogenic and shock reactions in host 
organisms. Therefore, the amounts of LPS in physiological solutions intended for intravenous 
injection are strictly specified.76 For HBOC formulations, the LPS content must be measured 
using a chromogenic Limulus Amoebocyte lysate (LAL) assay, although the charged protein 
and Hb absorption often hinder quantitative analysis. The high protein concentration inhibits 
enzyme cascade reactions, leading to a false-negative result. High Hb concentrations, 
meanwhile, can elevate the visible absorption and lead to false-positive results. The protein 
concentration of the HbBv–HSA3 cluster formulation is high (20 g/dL), and the sample must 
be diluted for measurements. 
In general, no standard method is available to remove LPS from a protein solution that is 
naturally contaminated with LPS.77,78 SEC and ultrafiltration are unsuitable to exclude LPS 
with widely various molecular weights (4 × 105 to 1 × 106 Da). Selective adsorption to the 
cationic polymer resin is applied for protein solutions, but both negatively charged LPS and 
proteins are adsorbed strongly by the matrix. Given these constraints, various adsorbents of 
aminated cellulose beads have been developed.79,80 They provide high removal efficiency of 
LPS and high recovery yields of the protein. 
In this study, the author prepared a sample solution of HbBv–HSA3 cluster, which was 
passed through a chromatography column with poly(ε-lysine)-immobilized cellulose beads 
(Cellufine ET-clean L; JNC Corp.). We measured the LPS content in the effluent by 
chromogenic LAL assay.81 Results demonstrated that (i) the eluent must be diluted by a factor 
of 1000 to avoid inhibition by the protein itself and HbBv absorption, (ii) one-shot passing of 
the 20 mg/mL cluster through the column chromatography can remove LPS efficiently, (iii) 
the LPS content decreased in proportion to the flow rate (Figure 2-11), and (iv) the LPS 
content fell below the detection limit of the apparatus (0.0001 endotoxin unit EU/mL) at a 
flow rate of 0.05 mL/min (recovery yield of the cluster = 94%). However, the dilution ratio of 
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the measured sample from the original formulation ([protein] = 200 mg/mL) was 10−4. We 
concluded that the measurement limit of LPS in the HbBv–HSA3 cluster formulation by 
chromogenic LAL assay was restricted to 1.0 EU/mL. 
 
 
Figure 2-11. Relationship between LPS concentration in the effluent and the flow rate in ET-clean 
L-column chromatography. The loaded sample ([HbBv–HSA3] = 20 mg/mL, 20 mL in PBS (pH 7.4), ionic 
strength μ = 0.16). The sample solution was passed through the column (0.75 cm internal diameter, 2.5 cm 
length) at 0.4−0.05 mL/min. The white point indicates [LPS] < 0.1 EU/mL. 
 
2.5.2 Experimental Section 
A poly(ε-lysine)-immobilized cellulose bead column (Cellufine ET-clean L, approximately 1 
mL, 0.75 cm internal diameter, 2.5 cm length; JNC Corp.) was washed with at least a 
10-column volume of 0.2 M NaOH and LPS free water. It was then equilibrated with PBS 
(pH 7.4, ionic strength (μ) of 0.16). The sample solution of HbBv–HSA3 ([protein] = 20 
mg/mL, 20 mL), which was contaminated naturally with LPS, was subjected to the column at 
flow rates of 0.4−0.05 mL/min. The LPS concentration of the effluent was measured by 
chromogenic LAL assay81 using an endotoxin-specific limulus reagent (Endospecy ES-24S 
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Kit, LAL, < 0.001 EU/mL; Seikagaku Biobusiness Corp.) and observed using a toxinometer 
(EG Reader SV-12; Seikagaku Corp.). 
 
2.7 Lyophilization of Hemoglobin–Albumin Cluster for Long-Term Storage 
2.7.1 Preparation of Lyophilized HbBv–HSA3 Cluster Powder 
Lyophilization is one of the most effective procedures to store proteins for extended periods.82 
However, freezing and drying cause denaturation, aggregation, and inactivation. To maintain 
the protein structure, sugars such as sucrose and trehalose (non-reducing disaccharides) are 
widely used as lyoprotectants.82–86 Nevertheless, the dioxygenated HbBv core in the cluster 
gradually oxidizes to ferric metHb, even at 4 °C, and eventually loses its O2-transporting 
ability. If the HbBv–HSA3 cluster solution was lyophilized without protein denaturation and 
metHb formation, the obtained powder and regenerated solution can be expected to be used in 
medical applications. The long-term-storable HbBv–HSA3 powder allows us to provide an 
RBC substitute by adding only water at any time. 
To prevent unfavorable oxidation, we added sucrose and trehalose, which are extensively 
used as lyoprotectants (5 g/dL; [sugar]/[protein] = 0.25 g/g or 15 g/dL; [sugar]/[protein] = 
0.75 g/g), to the HbBv–HSA3 cluster solution and lyophilized the resultant mixture, yielding a 
homogeneous pink powder (Figure 2-12). The powder could be redissolved in water, 
conferring a clear red solution. Native-PAGE and SEC patterns of the redispersed HbBv–
HSA3 cluster were identical to those before freeze-drying. The results imply that the cluster 
did not aggregate and degrade after redissolving in water. 
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Figure 2-12. Lyophilized HbBv–HSA3 cluster + sucrose 0.75 g/g. 
 
2.7.2 OxyHb rate and O2-Binding Property of Lyophilized HbBv–HSA3 Clusters 
Long-term storage of HbBv–HSA3 cluster requires suppression of autoxidation of the 
core Hb. Unfortunately, 20% of HbBv–HSA3 clusters (without any additive) were oxidized by 
lyophilization (Figure 2-13). The oxyHb rate decreased steadily and reached 50% after 2 
months, even at 4 °C. The value continued to decrease more slowly. However, the metHb rate 
was retarded depending on the amount of sugars. In particular, addition of sucrose 0.75 g/g 
showed the highest deterrence of metHb formation. The oxyHb rate remained at 94%, even 
after 2 years. The O2-binding parameters (P50, n) of HbBv–HSA3 cluster + sucrose 0.75 g/g or 
trehalose 0.75 g/g (P50 = 9 Torr, n = 1.4) were also identical to the value of original solution 
(Table 2-4).19,87 
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Figure 2-13. OxyHb rate of the lyophilized HbBv–HSA3 cluster containing sugar at 4 °C for 2 years. The 
HbBv–HSA3 cluster + sucrose 0.75 g/g: red, cluster + sucrose 0.25 g/g: orange, cluster + trehalose 0.75 g/g: 
blue, cluster + trehalose 0.25 g/g: light blue, cluster without sugar: black. 
 
 
 
 
 
 
 
2.7.3 Characterization of Lyophilized HbBv–HSA3 Clusters with CD Spectroscopy and 
FTIR Spectroscopy 
CD spectral patterns and intensities of the HbBv–HSA3 cluster + sucrose 0.75 g/g and HbBv–
HSA3 cluster + trehalose 0.75 g/g were unaltered before and after lyophilization (Figure 2-14). 
Furthermore, they coincided closely with the sum spectra of an HbBv and 3-fold enlarged 
HSA. We concluded that the secondary structure of HbBv–HSA3 cluster was maintained in 
the presence of sucrose 0.75 g/g or trehalose 0.75 g/g. 
Table 2-4. O2-binding parameters of regenerated solution HbBv–HSA3 cluster 
powder containing sucrose 15 wt% or trehalose 15 wt% after 2 years storage at 37 ºC 
Hemoprotein P50 (Torr) n (–) 
HbBv 23 2.6 
HbBv–HSA3 before lyophilization 9 1.4 
HbBv–HSA3 + Sucrose 0.75 g/g 9 1.4 
HbBv–HSA3 + Trehalose 0.75 g/g 9 1.4 
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Figure 2-14. CD spectra of HbBv solution, HSA solution, and regenerated aqueous solution of lyophilized 
HbBv–HSA3 cluster containing sucrose 0.75 g/g or trehalose 0.75 g/g after 2 years of refrigerator storage. 
These samples were measured at 25 °C. 
 
Generally, lyophilization of protein without a stabilizer denatures the 3-D structure of the 
protein by disrupting hydrogen bonds and causing denaturation and aggregation.83,84 The O2 
coordinated with the heme in Hb is also stabilized by the hydrogen bond, with a distal His in 
the heme pocket.88 Distortion of the heme pocket by dehydration induces oxidation of the 
heme.84 The coexistence of sucrose or trehalose preserves the protein structure in a natural 
conformation by creating hydrogen bonds instead of hydrate water molecules (water 
replacement theory).82,83,89 These protein-sugar interactions were confirmed by observation of 
hydrogen bonds between carboxylate groups of amino acids (Asp, Glu) and hydroxyl groups 
of sugar using infrared (IR) spectroscopy. Carpenter et al. reported that the antisymmetric 
COO− stretching band, vas(COO−), of the protein carboxylate formed a hydrogen bond with 
sugar and appeared at 1600‒1580 cm−1.90,91 We measured IR spectra of the lyophilized 
powder of HbBv–HSA3 + sucrose 0.75 g/g and HbBv–HSA3 + trehalose 0.75 g/g (Figure 
2-15). In the D2O solution of HbBv–HSA3 cluster, the vas(COO−) bands were observed at 
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1580 cm−1. The freeze-drying HbBv–HSA3 cluster in the presence of sucrose 0.75 g/g or 
trehalose 0.75 g/g resulted in retention of the carboxylate band (1579 cm–1). In contrast, the 
corresponding band was not detectable in lyophilized HbBv–HSA3 powder without an 
additive. The wavenumbers of vas(COO−) observed in HbBv–HSA3 (+ sucrose or trehalose) 
powder were relatively lower than those of lysozymes and α-lactalbumin (1584‒1582 
cm−1).90,91 We reasoned that this could be attributed to the difference in Asp and Glu 
contents.92,93 HSA possesses more Glu than Asp (Glu/Asp = 1.7), whereas lysozymes and 
α-lactalbumin have more Asp than Glu (Asp/Glu = 2‒4) (Table 2-5). Consequently, the peak 
position of vas(COO−) was governed by Glu (1567 cm−1) in the HbBv–HSA3 cluster and the 
values of others are governed by Asp (1584 cm−1). Our results revealed that the addition of 
sucrose 0.75 g/g or trehalose 0.75 g/g allowed us to prepare homogeneous powder of 
lyophilized HbBv–HSA3 clusters with original structural conformation and O2-binidng 
properties. 
 
Table 2-5. Number of aspartate (Asp) and glutamate (Glu) in proteins 
Protein Asp Glu 
Lysozyme C (chicken) 7 2 
α-lactalbumin (bovine) 13 6 
Hemoglobin (bovine) 34 26 
Human serum albumin 36 62 
HbBv–HSA3 142 212 
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Figure 2-15. IR spectra of an HbBv–HSA3 cluster solution in D2O (gray dotted line) and lyophilized 
powder of an HbBv–HSA3 cluster; without sugar (black solid line), + sucrose 0.75 g/g (red solid line), + 
trehalose 0.75 g/g (blue dashed line). 
 
Cleland et al. and Gieseler et al. investigated the relationship between an additive amount 
of sugar and the preservation stability of monoclonal antibodies and HSA.94,95 They concluded 
that 360 mol/mol (or more) of sugar is necessary to lyophilize the proteins without denaturation. 
In our case of 0.75 g/g, the molar ratios of sucrose and trehalose to HbBv–HSA3 clusters were 
565 and 517 mol/mol, respectively. These values were sufficient to maintain the 3-D structure 
of the protein. By contrast, 0.25 g/g, which corresponds to the molar ratio of 188 and 170 
mol/mol, respectively, for sucrose and trehalose, was unable to protect the HbBv–HSA3 
cluster, and the core Hb was partially oxidized.  
We supposed that trehalose shows superior protective ability compared with sucrose, 
because the glass transition temperature (Tg) of trehalose (117 °C) is higher than that of 
sucrose (65 °C).96 Unexpectedly, the addition of sucrose was effective for both 0.25 g/g and 
0.75 g/g. Lerbert et al., using a molecular dynamics simulation, reported that the number of 
hydrogen bonds between lysozyme and sucrose was larger than the value in trehalose.97 The 
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Tg of sucrose also reportedly rises to 90‒115 °C in the presence of phosphate.98 We inferred 
that these reasons enhanced the protection effect of sucrose on HbBv–HSA3 clusters. 
 
2.7.4 Experimental Section 
Preparation of Lyophilized HbBv–HSA3 Cluster Powder 
A carbonyl HbBv–HSA3 cluster in PBS solution (pH 7.4) ([HbBv unit] = 5 g/dL) was 
prepared according to our previously reported procedure.19 The solvent was replaced to 10 
mM PB (pH 7.4) using centrifugal filters (Amicon Ultra-15, 10 kDa MWCO). The phosphate 
concentration was almost adjusted to the value in PBS to maintain the pH at 7.4. The carbonyl 
HbBv–HSA3 cluster in PB was oxygenated by light irradiation and O2 gas aeration. To the 
oxy HbBv–HSA3 cluster solution ([HbBv unit] = 5 g/dL), sucrose or trehalose (5 g/dL; 
[sugar]/[protein] = 0.25 g/g, 15 g/dL; [sugar]/[protein] = 0.75 g/g) was added and the mixture 
was gently shaken to dissolve the sugar. The resultant solutions were frozen at −20 °C for 1 h 
and in liquid N2 bath for 5 min. Subsequently they were freeze-dried under reduced pressure 
for 14 h using a freeze dryer (FDU-1200; Tokyo Rikakikai Co., LTD.), yielding a lyophilized 
pink powder of oxy HbBv–HSA3 cluster. 
 
O2-Binding Property of Lyophilized HbBv–HSA3 Clusters 
The lyophilized powder of the HbBv–HSA3 cluster (+ sucrose or trehalose) stored in 
refrigerator (4 °C) was dissolved in water to regenerate an aqueous sample solution ([HbBv 
unit] = 10 μM). The oxyHb rate of HbBv–HSA3 cluster was calculated from absorption 
intensity at 630 nm based on ferric metHb.19 After the absorption spectral measurement of the 
sample, 40 mM K3Fe(CN)6 (6 μL) was added ([K3Fe(CN)6]/[HbBv unit] = 16 mol/mol) to 
prepare 100% ferric met HbBv–HSA3. The O2-binding parameters (P50, n) were determined 
from the O2-dissociation curve using an automatic recording system for the O2-equilibrium 
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curve (Hemox Analyzer; TCS Scientific Corp.) at 37 °C. 
 
Characterization of Lyophilized HbBv–HSA3 Clusters with CD and FTIR Spectroscopy 
The lyophilized powder of an HbBv–HSA3 cluster (+ sucrose or trehalose) was dissolved in 
water to regenerate an aqueous sample solution ([HbBv unit] = 0.2 μM) for CD spectral 
measurements. CD spectra were recorded using a CD spectrometer (J-820; Jasco Corp.) at 25 
ºC. 
The lyophilized powder of an HbBv–HSA3 cluster (+ sucrose or trehalose) was dissolved 
in D2O and incubated for 24 h to exchange hydrogen and deuterium (H/D exchange). IR 
spectrum of the sample solution was measured by a Fourier-transform infrared (FTIR) 
spectrometer (FT/IR-4000; Jasco Corp.) using a CaF2 cell (0.025 mm path length; Jasco 
Corp.). After the H/D exchange, the solution was freeze-dried as described above. The 
measurements of the solid samples were conducted using an FTIR spectrometer (Cary 630 
FTIR; Agilent Technologies Inc.) equipped with attenuated total reflection apparatus in an 
argon atmosphere in a glovebox. The wavenumber of vas(COO−) was determined from the 
second derivative of the original spectrum. 
 
2.8 Conclusions 
Using a cross-linker SMP, we performed the coupling reaction of HbBv and HSA at high 
protein concentrations to synthesize HbBv–HSA3 clusters. Purification using AEC can 
effectively separate HbBv–HSA3 clusters (pI 5.0) and unreacted HSA (pI 4.9). These 
improvements allowed us to prepare 74 ± 6 mL of HbBv–HSA3 cluster formulations at one 
time. These techniques are expected to become the basis of production procedures at a scale 
of several tens of liters at a pilot plant. The HbBv–HSA3 cluster and its components showed 
identical O2 affinity, implying that the O2-binding property of the cluster is unaffected by the 
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HSA binding number. The measurement limit of LPS in the HbBv–HSA3 cluster formulation 
by chromogenic LAL assay was found to be 1.0 EU/mL. The addition of sucrose 0.75 g/g (15 
wt%) and trehalose 0.75 g/g (15 wt%) to the HbBv–HSA3 cluster solution allowed us to 
prepare lyophilized powder in which oxyHb rate was retained for 2 years in a refrigerator at 
4 °C. The long-term-storable HbBv–HSA3 cluster powder is anticipated to become a useful 
artificial O2-carrier that can be regenerated to a desired concentration by adding water and 
transported anywhere at low cost.  
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Chapter 3 
 
Expression of Recombinant Human Hemoglobin A 
(Wild-Type) and Synthesis of Recombinant 
Hemoglobin–Albumin Clusters  
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3.1 Introduction 
Nagai et al. first reported recombinant HbA (rHbA) expressed in an Escherichia coli host cell 
in the 1980s.99,100 It is now recognized that transgenic bacteria systems have some 
shortcomings: misfolding, remaining N-terminus methionine, and risk of endotoxin (LPS) 
contamination.101–103 Hoffman (Somatogen Inc.) and Ho et al. reported an α- and β-globin 
co-expression system with methionine aminopeptidase (Met-AP) co-expression using E. 
coli.104,105 Several others have reported rHbA expression systems using insect cells of 
Spodoptera frugiperda (Sf-10)106 and the yeast Saccharomyces cerevisiae.107,108 However, 
there has been no report on a Pichia pastoris system. In this study, the author aimed to 
establish an rHbA expression system using P. pastoris and prepare synthetic HBOC in the 
form of an rHbA–rHSA3 cluster, independent of donated blood. 
 
3.2 Expression of Recombinant Human Hemoglobin A (Wild-Type) by 
Pichia Yeast 
3.2.1 Construction of Recombinant Human Hemoglobin A (Wild-Type) Expression 
Plasmid Vector 
The author described the efficient preparation of an HbBv–HSA3 cluster in Chapter 2. The 
same approach can be applied to the synthesis of a cluster using HbA, an HbA–HSA3 cluster. 
However, using HbA–HSA3 requires regularly securing a certain amount of raw HbA from 
outdated human RBC. If the raw materials of the cluster were replaced with recombinant 
proteins, an entirely synthetic O2-carrier could be produced without donated blood. Komatsu 
et al. described human, dog (canine), and cat (feline) expression systems of for serum 
albumins using methylotrophic (methanol assimilation) P. pastoris.58,109,110 
The aim of the second study was to establish an expression system using Pichia for 
rHbA(wt) with amino acid sequences and a 3-D structure identical to those of native HbA. 
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Although Pichia yeast can be constructed as a secretory system, we prepared an intracellular 
expression system of rHbA to avoid of the risk of heme oxidation (Figure 3-1). 
 
 
Figure 3-1. Schematic illustration of construction of pHIL-D2-HbA(αβ) expression vector. 
 
An rHbA(wt) expression vector, pHIL-D2-HbA(αβ), was prepared using general 
procedures with complementary DNA (cDNA) of HbA α- and β-globins. Construction of each 
vector was checked by agarose-gel electrophoresis. The agarose-gel electrophoresis of the 
HindIII-digested pHIL-D2-HbA(α) and pHIL-D2-HbA(β) showed two bands based on 
pHIL-D2 fragments and each HbA cDNA region (Figure 3-2). Similarly, agarose-gel 
electrophoresis of pHIL-D2-HbA(αβ) after an In-Fusion reaction indicated insertion of a 
5’AOX1-HbA(β)-3’AOX1(TT) fragment into pHIL-D2-HbA(α) (Figure 3-3). Insertion of the 
entire HbA α- and β-globins coding region was confirmed using DNA sequencing analysis. 
Finally, the P. pastoris was transformed with linearized pHIL-D2-HbA(αβ) by SalI digestion. 
 
46 
 
 
Figure 3-2. Insert check of HbA(α) and HbA(β) regions by 2% agarose-gel electrophoresis of 
pHIL-D2-HbA(α) and pHIL-D2-HbA(β) by HindIII treatment. 
 
 
 
Figure 3-3. The 0.8% agarose-gel electrophoresis of (A) 5’AOX1-HbA(β)-3’AOX1(TT) fragment and 
linearized pHIL-D2-HbA(α) by BstZ17I treatment, and (B) pHIL-D2-HbA(αβ) fragments digested by SacI. 
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3.2.2 Expression and Purification of Recombinant Human Hemoglobin A (Wild-Type) 
Expression was performed according to a standard protocol using methanol induction with 
some modification. Specifically, we added hemin to the methanol induction medium. 
Although the Pichia yeast involves a heme biosynthesis pathway, Spadiut et al. reported that 
the addition of hemin to the cultivation medium increased the yield of the target 
hemoprotein.111 The rHbA(wt) showed unexpected fluorescence (550–700 nm), which 
resembles that of Zn(II)-substituted HbA. We inferred that a small amount of apo-protein 
without heme captures Zn(II)-protoporphyrin IX to generate Zn(II)–rHbA(wt). The addition 
of hemin (0.3 mM) to the medium rendered the fluorescence intensity negligible, implying 
that hemin is necessary to produce high yields of rHbA(wt). SDS-PAGE and native-PAGE 
analysis of rHbA(wt) depicted only two or one band, respectively, in the same positions as 
those of the α- and β-globins of native HbA (Figure 3-4). The purity of rHbA(wt) calculated 
by SDS-PAGE was more than 99%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. (A) SDS-PAGE and (B) native-PAGE patterns of native HbA, cell lysate, and rHbA(wt). 
48 
 
3.2.3 Experimental Section 
Construction of a Recombinant Human Hemoglobin A (Wild-Type) Expression Plasmid 
Vector 
The plasmid vectors were constructed by polymerase chain reaction (PCR) using a 
PrimeSTAR Max DNA polymerase and In-Fusion HD cloning kit (Takara Bio Inc.). The 
plasmid containing human α-globin [HbA(α)] cDNA, pEx-A2J1-HbA(α) (2,760 bp), and the 
plasmid containing HbA(β) cDNA, pEx-A2J1-HbA(β) (2,775 base pairs [bp]), were provided 
by Prof. Satoru Unzai, Hosei University. The full-length of cDNA of HbA(α) and HbA(β) 
were amplified by PCR using the following oligonucleotide primer set: α-globin forward 
[5’-TCGAAACGAGGAATTATGGTTCTGTCACCAGCG-3’], α-globin reverse 
[5’-TGTCTAAGGCGAATTAGCGATATTTGCTGGTCAG-3’], β-globin forward 
[5’-TCGAAACGAGGAATTATGGTGCATCTGACGCCG-3’], and β-globin reverse 
[5’-TGTCTAAGGCGAATTAATGGTATTTGTGAGCAAGC-3’]. The PCR products were 
checked by 3% agarose-gel electrophoresis along with a standard marker (100 bp DNA 
ladder). The amplified fragment was cloned into the EcoRI site of the pHIL-D2 plasmid using 
In-Fusion cloning, yielding pHIL-D2-HbA(α) (8,641 bp) and pHIL-D2-HbA(β) (8,656 bp). 
Insertion of the entire HbA α- and β-globins coding region was confirmed using DNA 
sequencing analysis. Next, the expression cassette of the 5’alcohol oxidase 1 
(AOX1)-HbA(β)-3’AOX1(TT) was amplified by PCR using following oligonucleotide primer 
set: β2-forward [5’-ATAGTTAAGCCAGTAGATCTAACATCCAAAGACGA-3’] and 
β2-reverse [5’-CGATAGCGGAGTGTAAGCTTGCACAAACGAACTTC-3’]. The amplified 
fragment was subsequently cloned into the BstZ17I site of the pHIL-D2-HbA(α) plasmid 
using In-Fusion cloning, yielding pHIL-D2-HbA(αβ) (10,369 bp). This plasmid vector was 
linearized by SalI digestion and introduced into the GS115 strain of P. pastoris (Thermo 
Fisher Scientific K.K.) by electroporation using an Electroporator (MicroPulser; Bio-Rad 
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Laboratories, Inc.). 
 
Expression and Purification of Recombinant Human Hemoglobin A (Wild-Type) 
Expression of rHbA(wt) was conducted by standard protocols provided by Thermo Fisher 
Scientific K.K. with some modifications. Transformed clone cells were grown in a buffered 
mineral glycerol-complexes medium (total 4 L) in a shaking incubator (Bio-Shaker 
G‧BR-200; Taitec Corp.) (30 °C, 200 rpm). Subsequently, the growth cell was resuspended in 
a buffered mineral methanol-complexes medium containing 0.3 mM hemin (Fujifilm Wako 
Pure Chemical Corp.). To induce expression, the suspension was shaken in an incubator 
(30 °C, 200 rpm) for 7 days. During the cultivation, methanol (1.5% volume of medium) was 
added every 24 h. The induced medium was centrifuged and washed with a 20 mM sodium 
PB (pH 6.0) containing 1 mM phenylmethylsulfonyl fluoride. The cells were then disrupted 
using a homogenizer (BeadBeater; BioSpec Products Inc.) with 0.5 mm glass beads. After 
centrifugation (12,000 g for 1 h), the obtained supernatant was flowed through CO gas to 
avoid rHbA(wt) oxidation. The lysate was subjected to CEC with an SP Sepharose Fast Flow 
(GE Healthcare UK Ltd.) using 20 mM PB (pH 6.0) as the running buffer. After flushing the 
same buffer to exclude unnecessary proteins and contaminated nucleic acids, the rHbA(wt) 
was eluted with 50 mM Tris-HCl (pH 8.0) and loaded onto AEC with a Q Sepharose Fast 
Flow (GE Healthcare UK Ltd.) using 50 mM Tris-HCl (pH 8.0). The rHbA(wt) was eluted by 
PBS (pH 7.4). The rHbA(wt) was dialyzed against the PBS solution using centrifugal filters 
(Amicon Ultra 15, 10 kDa MWCO; Merck Millipore Ltd.) and transferred into a 50 mL glass 
flask sealed with a rubber septum. After the CO gas flowed into the flask to prepare carbonyl 
rHbA(wt), the solution was heated at 70 ºC for 2 h with gentle stirring in the dark. Finally, the 
resulting solution was centrifuged (3000 g at 4 ºC) for 20 min to remove the precipitate. 
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3.3 Structure and O2-Binding Property of Recombinant Human 
Hemoglobin A (Wild-Type) 
3.3.1 Structure of Recombinant Human Hemoglobin A (Wild-Type) 
The CD spectrum of rHbA(wt) coincided with that of native HbA (Figure 3-5), suggesting 
that their secondary structures are equivalent. 
 
 
 
 
 
 
 
 
 
Figure 3-5. The CD spectra of native HbA (black dotted line) and rHbA(wt) (orange solid line) in a PBS 
solution (pH 7.4) at 25 °C. 
 
When expressed in E. coli, rHbA(wt) contains an abnormal isomer in which the 
asymmetric prosthetic heme group is rotated 180° to the α-δ axis of porphyrin (Figure 
3-6A).112,113 This reversed heme form of rHbA(wt) exhibits high O2 affinity and low 
O2-binding cooperativity. Nagai et al. determined the percentage of heme orientation in the 
rHbA by 1H nuclear magnetic resonance spectroscopy. The CD spectral pattern of carbonyl 
rHbA and the negative CD band at 413 nm indicated the presence of reversed heme (Figure 
3-6B).113 The visible CD spectrum of our rHbA(wt) after AEC showed a small negative band 
at 413 nm. The reversed heme ratio in this sample was estimated at 30%. However, in the CD 
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spectrum of the heat-treated rHbA(wt) sample, the negative CD band disappeared. The whole 
spectrum was identical to that of native HbA. This suggests that the two heme orientations 
were aligned in their natural form, which is thermodynamically favored. 
 
 
 
 
 
 
 
 
 
 
Figure 3-6. (A) The chemical structure of normally heme orientation and proximal His in HbA, (B) CD 
spectra of each fraction in SP column (percentage of normally orientation; blue: 88%, green: 49%, red: 
14%, respectively).113 
 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrum 
of the rHbA(wt) showed molecular ion peaks at 15,128 and 15,869 Da, which were almost 
identical to those of theoretical masses of the α- and β-globins, respectively (± 0.02%) (Table 
3-1). These results indicate that the extra N-terminal methionine was cleaved completely. 
 
 
 
 
Table 3-1. MALDI-TOF mass spectral data of rHbA(wt) (mean ± SD, n = 3) 
Sample Observed (Da) Calculated (Da) 
α-globin 15,128.1 ± 0.6 15,126 
β-globin 15,869.3 ± 1.3 15,867 
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By crystallizing carbonyl rHbA(wt) under a microgravity environment in the Japanese 
Experimental Module “Kibo” of the International Space Station (ISS), the 3-D structure of 
carbonyl rHbA(wt) was revealed by X-ray diffraction measurement at 2.3 Å resolution. 
Crystals of carbonyl rHbA(wt) belong to the monoclinic space group P 1 21 1 (Table 3-2). As 
expected, the superimposed images of rHbA(wt) (PDB ID: 6KYE) and carbonyl native HbA 
(PBD ID: 2DN3)114 illustrate the near-identical configurations of the 4 subunits (Figure 3-7A). 
Root mean square deviation value of the polypeptide Cα atoms of these proteins was within 
0.51 Å. We confirmed that the N-terminates of α- and β-globins are both valines, and the 
heme orientations are aligned in the normal form. Typical salt bridges in the triads of carbonyl 
HbA (Asp-α194, Trp-β237, and Asn-β2102), which stabilize the R-state conformation,114 were 
also definitively identified in carbonyl rHbA(wt) (Figure 3-7B). 
 
 
 
 
 
 
 
 
Figure 3-7. (A) X-ray crystallography of carbonyl rHbA(wt) (PDB ID: 6KYE; α-globin: red, β-globin: 
pink), and (B) superimposed structure of carbonyl native HbA (PDB ID: 2DN3) and carbonyl rHbA(wt), 
which are characteristic salt bridges stabilizing the R-state. 
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Table 3-2. X-ray crystallography data collection and refinement statistics of rHbA(wt) 
Wavelength (Å) 1.0000 
Resolution range (Å) 48.42–2.28 (2.33–2.28) 
Space group P 1 21 1 
Cell dimensions 
a = 123.031 Å, b = 55.947 Å, c = 133.156 Å 
α = 90.00°, β = 98.27°, γ = 90.00° 
Total reflections 233,642 
Unique reflections 80,208 (12,565) 
Multiplicity 2.9 (2.9) 
Completeness (%) 97.6 (93.6) 
Mean I/sigma (I) 5.4 (0.7) 
Rmeas 0.17 (1.984) 
Rpim 0.095 (1.116) 
CC(1/2) 0.993 (0.338) 
Refinement  
Resolution range (Å) 48.42–2.28 
No. reflections 80,196 
Rwork/Rfree 0.226/0.268 
No. atoms  
Amino acids 13085 
Ligands 540 
Waters 139 
B-factors  
Amino acids 54.41 
Ligands 49.46 
Waters 43.19 
RMS (bonds) 0.0039 
RMS (angles) 1.337 
Ramachandran favored (%) 95.98 
Ramachandran outliers (%) 0.18 
Clashscore 6.28 
Statistics for the highest-resolution shell are shown in parentheses. 
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3.3.2 O2-Binding Parameters of rHbA(wt) 
The visible absorption spectral patterns of rHbA(wt) under N2, O2, and CO atmospheres 
(deoxy, oxy, carbonyl forms) were fundamentally equivalent to those of native HbA (Figure 
3-8A, Table 3-3). The O2-dissociation curves of rHbA(wt) and native HbA in a PBS solution 
(pH 7.4, at 37 °C) also showed close agreement. The P50 and the Hill coefficient (n) of 
rHbA(wt) were 11 Torr and 2.3, respectively (Figure 3-8B). O2-complex stability of rHbA(wt) 
in PBS solution (pH 7.4) was evaluated using the autoxidation rate constant (kox) at 37 °C. 
The kox value of rHbA(wt) was determined to be 0.028 h−1 (Table 3-4), which is a similar 
value to that of native HbA (kox = 0.020 h−1). We concluded that the maximum absorption 
wavelength (λmax), P50, n, and kox values of rHbA(wt) were almost identical to those observed 
for native HbA. 
 
 
 
 
 
 
 
 
 
 
Figure 3-8. The O2-binding properties of the rHbA(wt). (A) Visible absorption spectra of the rHbA(wt) in 
oxy (red), deoxy (blue), carbonyl (green) forms in a PBS solution (pH 7.4) at 25 °C, (B) O2-dissociation 
curves of native HbA (black dotted line) and rHbA(wt) (orange solid line) in PBS solution (pH 7.4) at 
37 °C. 
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Table 3-4. The O2-binding parameters of native HbA and rHbA(wt) in PBS 
solution (pH 7.4) at 37 °C 
Hemoprotein P50 (Torr) n (–) kox (h−1) 
HbA 12 2.4 0.020 
rHbA(wt) 11 2.3 0.028 
 
3.3.3 Experimental Section 
CD Spectroscopy and Mass Spectroscopy of rHbA(wt) 
The secondary structure and heme orientation of rHbA(wt) were confirmed by CD 
spectroscopy using a CD spectrometer (J-820; Jasco Corp.). The rHbA(wt) concentration of 
the sample was adjusted to [HbA] = 0.2 μM in PBS solution (pH 7.4) for the far-ultraviolet 
CD region (200–250 nm) and [HbA] = 3 μM in PBS for the visible CD region (230–500 nm), 
respectively, at 25 °C. The mass spectra were obtained using a MALDI-TOF mass 
spectrometer (ultrafleXtreme; Bruker Japan K. K.). 
 
Crystallization, Data Collection, and Structure Determination of Recombinant Human 
Hemoglobin A (Wild-Type) 
The crystallization of rHbA(wt) was conducted in the “Kibo” module of the ISS. The solution 
samples were launched aboard a Progress MS-11 spacecraft (72P) from the Baikonur 
Cosmodrome (Kazakhstan). Crystal growth in space was performed in a portable space 
freezer, FROST2, in Kibo. Red crystals (0.15 × 0.05 × 0.05 mm) grew from a 20 mg/mL 
protein solution in 26% PEG3350, 0.2 M NaCl, and 0.1 M MES (pH 6.0) at 293 K. After the 
Table 3-3. The UV-visible spectral data of native HbA and rHbA(wt) in PBS solution (pH 
7.4) at 25 °C 
Sample 
λmax (nm) 
oxy deoxy carbonyl 
Native HbA 414, 541, 577 430, 555 420, 539, 569 
rHbA(wt) 415, 541, 576 430, 555 419, 539, 569 
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grown crystals returned to Earth aboard the Soyuz MS-11 spacecraft (57S), they were 
flash-frozen in liquid N2. XRD data were collected using an EIGER X 16M (Dectris USA 
Inc.) detector with a synchrotron radiation source at the SPring-8 beamline BL41XU (Hyogo, 
Japan). All data were collected at 100 K and processed with XDS (Table 3.4).115 The 
rHbA(wt) structure was ascertained using molecular replacement with PHASER in 
CCP4.116,117 The native carbonyl HbA structure (PDB ID: 2DN3) was used as the search 
model.118 The sequence assignment of the atomic model was conducted using the amino acid 
sequence for HbA [UniProt ID: P69905; HbA(α), P68871; HbA(β)]. Further iterative 
model-building and refinement were performed using refmac and COOT.119–122 Atomic 
coordinates of the rHbA(wt) structure reported in this study were deposited in the PDB under 
accession code 6KYE. All molecular images were produced using PyMOL (Schrödinger 
LLC). 
 
O2-Binding Property of rHbA(wt) 
The preparation of oxy and deoxy forms was conducted by the same procedure as with HbBv. 
To prepare oxy rHbA(wt), O2 gas was flowed to the PBS solution of the carbonyl rHbA(wt) 
([HbA] = 3 μM, 3 mL) in a 10 mm optical quartz cuvette sealed with a rubber septum under 
LED light irradiation (50 W) in an ice-water bath. Then, N2 gas was flowed continuously and 
20 μM sodium dithionite (in a PBS solution) was added to the oxy form solution, yielding 
deoxy rHbA(wt). The autoxidation rate constant (kox) of the rHbA(wt) was determined from 
absorption intensity at 630 nm with time under aerobic conditions at 37 °C.123 The O2-binding 
parameters (P50, n) were ascertained from the O2-dissociation curve, which was observed by 
an automatic recording system for the O2-equilibrium curve (Hemox Analyzer) in PBS (pH 
7.4) at 37 °C ([HbA] = 10 μM). 
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3.4 Synthesis of Recombinant Hemoglobin–Albumin Cluster 
3.4.1 Synthesis of rHbA(wt)–rHSA3 Cluster 
The rHbA(wt)–rHSA3 cluster was prepared according to the procedure described in Chapter 2. 
The yield of rHbA(wt)–rHSA3 clusters was 58% based on rHbA(wt) (Figure 3-9A). The 
average binding number of rHSA on the rHbA(wt) core was 3.0 as measured by protein and 
Hb assays. The CD spectrum of rHbA(wt)–rHSA3 clusters coincided well with the sum of the 
rHbA(wt) spectrum and rHSA spectrum, which was enlarged by a factor of 3 (Figure 3-9B). 
The major component of the rHbA(wt)–rHSA3 cluster is a heterotetramer. The 4.5-fold molar 
excess rHSA was sufficient to synthesize the rHbA(wt)–rHSA3 cluster, because the mercapto 
rate of Cys-34 in rHSA (as a percentage of free sulfhydryl groups) was higher (by 
approximately 75%) than that of HSA (40–50%). 
 
 
 
 
 
 
 
 
 
Figure 3-9. (A) SEC profiles of the reaction mixture (black dotted line; MA-rHbA[wt] + rHSA) and 
rHbA(wt)–rHSA3 cluster (red solid line) and (B) the CD spectra of rHbA(wt) (orange solid line), rHSA 
(green solid line), rHbA(wt)–rHSA3 cluster (red solid line) in PBS (pH 7.4) at 25 °C. 
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3.4.2 Experimental Section 
A DMSO solution of SMP (150 mM, 0.1 mL) was added dropwise into carbonyl rHbA(wt) (1 
mM, 1 mL) in PBS (pH 7.4). After the mixture was stirred for 30 min at 4 ºC, unreacted 
cross-linkers in the reactant were removed using GFC, and MA-rHbA(wt) was concentrated 
to 3 mL ([HbA] = 0.33 mM). A PBS solution of rHSA (2.25 mM, 2 mL) was then added to 3 
mL of the MA-rHbA(wt) with stirring for 70 h at 4 ºC. Next, 2 mL of the resulting reaction 
mixture was subjected to AEC with HiTrap Q Sepharose Fast Flow (GE Healthcare UK Ltd.) 
using PBS as the running buffer. After flushing of PBS containing 30 mM NaCl (pH 7.4) to 
remove excess rHSA, the rHbA(wt)–rHSA3 cluster was eluted with PBS containing 160 mM 
NaCl. Finally, the eluent was dialyzed against PBS (pH 7.4) using centrifugal filters (Amicon 
ultra 15, 10 kDa MWCO). A thiol assay of rHSA was performed by reacting it with 
4,4’-dithiopyridine, which binds the sulfhydryl group of the protein to generate 
4-thiopyridinone (4-TP, ε324 = 1.98 × 104 M−1 cm−1).124 
 
3.5 O2-Binding Property of Recombinant Hemoglobin–Albumin Cluster 
3.5.1 O2-Binding Property of Recombinant Hemoglobin–Albumin Cluster 
The visible absorption spectral patterns of rHbA(wt)–rHSA3 clusters of deoxy, oxy, and 
carbonyl forms were identical to those of rHbA(wt) (Table 3-5). By contrast, the P50 and the 
Hill coefficient (n) of rHbA(wt)–rHSA3 clusters (8 Torr, 1.4) showed moderately lower values 
compared with naked rHbA(wt). (Figure 3-10, Table 3-6). Moreover, the autoxidation rate 
constant (kox) value of rHbA(wt)–rHSA3 clusters in PBS (pH 7.4) was 0.038 h−1 (Table 3.5), 
which showed a slightly higher value of rHbA(wt) (kox = 0.028 h−1), was identical to that of 
the HbA–HSA3 clusters. The coupling of a cross-linker such as SMP on rHbA(wt) generally 
increases O2 affinity and decreases cooperatively. This can be attributed either to chemical 
modification of the surface Lys group on core Hb or the covalent connection of SMP to the 
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Cys-β93 in core Hb. Details are described in Chapter 2. 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. The O2-dissociation curves of rHbA(wt) (orange) and its cluster (red) in PBS solution (pH 
7.4) at 37 °C. 
 
 
 
 
 
 
3.5.2 Experimental Section 
To prepare oxy rHbA(wt), O2 gas was flowed to the PBS solution of the carbonyl rHbA(wt)–
rHSA3 cluster ([HbA unit] = 10 μM, 3 mL) in a 10 mm optical quartz cuvette sealed with a 
Table 3-5. The UV-visible spectral data of rHbA(wt) and its cluster in PBS solution (pH 7.4) 
at 25 °C 
Sample 
λmax (nm) 
oxy deoxy carbonyl 
rHbA(wt) 415, 541, 576 430, 555 419, 539, 569 
rHbA(wt)–rHSA3 414, 541, 576 430, 555 419, 539, 569 
Table 3-6. The O2-binding parameters of native HbA, rHbA(wt), and its clusters in 
PBS solution (pH 7.4) at 37 °C 
Hemoprotein P50 (Torr) n (–) kox (h−1) 
HbA 12 2.4 0.020 
HbA–HSA3 8 1.4 0.038 
rHbA(wt) 11 2.3 0.028 
rHbA(wt)–rHSA3 8 1.4 0.038 
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rubber septum under a 50 W LED lamp in an ice-water bath. Then, N2 gas was flowed 
continuously and 20 μM sodium dithionite (6 μL) was added to the oxy form solution, 
yielding deoxy an rHbA(wt)–rHSA3 cluster. The autoxidation rate constant (kox) of the 
rHbA(wt)–rHSA3 cluster was determined from the absorption intensity at 630 nm with time 
under aerobic conditions at 37 °C. O2-binding parameters (P50, n) were determined using a 
Hemox Analyzer at 37 °C. 
 
3.6 Conclusion 
We established an rHbA(wt) expression system using P. pastoris and a purification procedure. 
The heme orientation disorder was aligned to the norm by heating at 70 °C. The structure of 
rHbA(wt) coincided perfectly with that of native HbA, as confirmed by MALDI-TOF 
spectroscopy, CD spectroscopy, and X-ray crystal structural analysis. The ultraviolet 
(UV)-visible absorption pattern and O2-binding property of rHbA(wt) were also identical to 
those of native HbA. We synthesized an rHbA(wt)–rHSA3 cluster, and revealed that its 
structure and O2-binding parameters were identical to those reported for an HbA–HSA3 
cluster. The genetically engineered rHbA(wt)–rHSA3 cluster is independent of donated blood, 
and is expected to serve as an entirely synthetic RBC substitute and O2-therapeutic reagent.  
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Chapter 4 
 
Synthesis of Recombinant Hemoglobin–Albumin 
Clusters with a Genetically Engineered Heme Pocket
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4.1 Introduction 
The O2 affinity of rHbA(wt)–rHSA3 clusters (P50 = 8 Torr) is somewhat higher than that of 
human RBC (P50 = 25 Torr). We believe that regulation of O2 affinity is useful not only for 
blood transfusion but other O2-based therapeutic applications as well. There are two 
approaches to reducing the O2 affinity of rHbA. First, disruption of the R-state–stabilizing salt 
bridges by mutagenesis moves the quaternary structure of Hb transition to the T state, which 
has low O2 affinity. For example, Hb Kansas (βN102T) and Hb Titusville (αD94N) are 
T-state–stabilizing abnormal forms of Hb, in which the R-state–stabilizing salt bridge 
between Asp-α94 and Asn-β102 is disrupted.125–127 Second, introduction of the mutation in the 
heme pocket decreases O2 affinity. Hydrogen bonds between distal His (E7 position: α58, 
β63) and the coordinated O2 molecule,128–130 and Leu at B10 position (α29, β28) affect steric 
hindrance to O2 binding.131–133 In the Hb–HSA3 cluster, control of O2 affinity by the T-R 
transition was difficult, because the core Hb was fixed in a near R-state.87 Therefore, we used 
the second approach and prepared 4 rHbA variants, replacing Leu-β28 and/or His-β63 with 
Phe (rHbA[βL28F]), Trp (rHbA[βL28W]), Gln (rHbA[βH63Q]), Tyr/Gln 
(rHbA[βL28Y/βH63Q]), respectively (Figure 4-1). Furthermore, their clusters have been 
synthesized. 
 
Figure 4-1. Structure of the mutated position of the heme pocket in β-globin. 
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4.2 Expression of Recombinant Hemoglobin with a Mutated Heme Pocket 
4.2.1 Mutagenesis and Expression of rHbA Variants 
The construction of 4 rHbA(X) (X = βL28F, βL28W, βH63Q, and βL28Y/βH63Q) variant 
expression plasmids was performed by site-specific mutation using a QuikChange II XL 
site-directed mutagenesis kit (Agilent Technologies Inc.). A sequence analysis revealed that 
all the plasmids included the target codon sequence. The rHbA(X) variant expression 
plasmids were linearized by SalI and transformed P. pastoris (GS115 strain), by 
electroporation, as with rHbA(wt). 
Expression and purification of all rHbA(X) variants were carried out following a 
procedure similar to that used for rHbA(wt). However, purification of rHbA(βL28W) was 
conducted without heat treatment because its denaturation temperature (Tm) in carbonyl form 
was 65 °C, which is 13 °C lower than that of native HbA (Tm = 78 °C) (Table 4-1). The Tm 
values were determined from CD spectral changes to be 25 °C to 90 °C at 222 nm of α-helices. 
It is described in detail in the experimental section. 
 
 
 
 
 
 
 
SDS-PAGE of each rHbA(X) variant depicted only two bands, which were in positions 
identical to those of native HbA (Figure 4-2). The CD spectral patterns of 3 rHbA(X) variants 
(X = βL28F, βL28W, and βH63Q) were identical to that of native HbA (Figure 4-3). Only 
rHbA(βL28Y/βH63Q) showed a CD spectral pattern that was slightly different from that of 
Table 4-1. Denaturation temperature and set temperature for heat treatment of each 
rHbA(X) variants 
Hemoglobin Denaturation temp. (°C) Heating temp. (°C) 
Native HbAa 78 – 
rHbA(βL28F) 73 70 
rHbA(βL28W) 65 – 
rHbA(βH63Q) 71 68 
rHbA(βL28Y/βH63Q) 68 61 
a Ref. 134. 
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native HbA. In general, the CD spectrum of α-helical structure has two characteristic negative 
peaks at 208 nm (π-π* parallel transition) and 222 nm (n-π* transition).135 Doig and Hirst 
reported that Tyr conformation affects the intensity of CD at 220 nm within ± 5000 deg‧cm2 
dmol−1.136,137 We inferred that rHbA(βL28Y/βH63Q) exhibited different CD spectral pattern 
from other rHbA(X)s. 
 
 
 
 
 
 
 
 
 
Figure 4-2. SDS-PAGE analysis of native HbA and rHbA(X) variants: (A) rHbA(βL28F), (B) 
HbA(βL28W), (C) rHbA(βH63Q), and (D) rHbA(βL28Y/βH63Q). 
 
 
 
 
 
 
 
Figure 4-3. CD spectra of native HbA and rHbA(X) variants in PBS (pH 7.4) at 25 °C. (A) Native HbA: 
black dotted line; rHbA(βL28F): red solid line; rHbA(βL28W): blue dashed line. (B) Native HbA: black 
dotted line; rHbA(βH63Q): orange solid line; rHbA(βL28Y/ βH63Q): green dashed line. 
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In addition, the MALDI-TOF mass spectra of the 4 rHbA(X) variants (X = βL28F, 
βL28W, βH63Q, and βL28Y/βH63Q) exhibited almost the same values as those of the 
theoretical mass of each β-globin mutant (Table 4-2). 
 
 
 
4.2.2 O2-Binding Properties of rHbA Variants 
Each maximum absorption wavelength (λmax) in oxy, deoxy, and carbonyl forms of four 
rHbA(X) variants (X = βL28F, βL28W, βH63Q, and βL28Y/βH63Q) exhibited values almost 
equal to those of native HbA (Table 4-3). The P50 values were 32 Torr for rHbA(βL28F), 60 
Torr for rHbA(βL28W), 11 Torr for rHbA(βH63Q), and 43 Torr for rHbA(βL28Y/βH63Q) 
(Table 4-4). 
Table 4-2. MALDI-TOF mass spectral data of rHbA(X) variants (mean ± SD, n = 3) 
Hemoglobin 
α-globin (Da) β-globin (Da) 
Observed Calculated Observed Calculated 
rHbA(βL28F) 15,128.1 ± 1.8 15,126.2 15,903.5 ± 1.9 15,901.0 
rHbA(βL28W) 15,129.3 ± 0.8 15,126.2 15,942.6 ± 1.1 15,940.1 
rHbA(βH63Q) 15,134.6 ± 0.7 15,126.2 15,863.5 ± 3.2 15858.0 
rHbA(βL28Y/βH63Q) 15,126.9 ± 0.0 15,126.2 15,909.2 ± 0.1 15,908.0 
Table 4-3. Visible absorption spectral data of native HbA and rHbA mutants in PBS 
solution (pH 7.4) at 25 °C 
Hemoglobin 
λmax (nm) 
oxy deoxy carbonyl 
Native HbA 414, 541, 577 430, 555 420, 539, 569 
rHbA(βL28F) 415, 541, 577 430, 555 419, 539, 569 
rHbA(βL28W) 415, 541, 577 430, 556 419, 538, 569 
rHbA(βH63Q) 415, 541, 577 430, 555 419, 540, 569 
rHbA(βL28Y/βH63Q) 414, 540, 576 430, 555 420, 539, 569 
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The O2 affinities (P50 values) of the rHbA(X) variants with mutated Leu-β28 were similar 
to those of the previous reports.133,138 Olson et al. reported O2-association-rate constants 
(konO2) of the rHbA(βL28F) and rHbA(βL28W) mutants in the R-state by laser flash 
photolysis.139 The high P50 value (low O2 affinity) of the rHbA(βL28W) mutant can be 
attributed to the bulky Trp side group (indole ring) at the β28 position, which reduced the 
room for the distal heme pocket cavity, causing an approximately 4,800-fold reduction in the 
konO2 value. In contrast, the konO2 value of the α-globin was unchanged. Brunori et al. reported 
that the konO2 value of β-globin in rHbA(βL28Y/βH63Q) was 3.6 times higher than that of 
native HbA.140 The Tyr at the β28 position generates a hydrogen bond with Gln at the β63 
position, which introduces steric hindrance of O2-binding to the heme iron. 
In the case of the rHbA(βH63Q) mutant, we expected low O2 affinity similar to opossum 
Hb [Hb(αH58Q)].130,141,142 However, our results showed the same O2 affinity as native HbA. 
 
4.2.3 Experimental Section 
Mutagenesis and Expression of rHbA Variants 
Site-directed mutagenesis of the rHbA(wt) expression plasmid pHIL-D2-HbA(αβ) employed 
the standard protocol of the QuikChange II XL kit (Agilent Technologies). All mutagenic 
primers containing desired mutation were purchased from Fasmac Co., Ltd. (Table 4-5). The 
Table 4-4. O2-binding parameters of native HbA and rHbA mutants in PBS (pH 7.4) at 37 °C 
Hemoglobin P50 (Torr) n (–) kox (h−1) 
Native HbA 12 2.4 0.020 
rHbA(βL28F) 32 1.8 0.122 
rHbA(βL28W) 60 1.5 0.075 
rHbA(βH63Q) 11 2.0 0.026 
rHbA(βL28Y/βH63Q) 43 1.5 0.047 
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transformation of Pichia yeast using the rHbA(X) expression plasmid followed the same 
procedure used for rHbA(wt). 
 
Expression and column purification of all rHbA(X) variants were conducted by the 
procedure uses for rHbA(wt). The temperatures during heat treatment process of 
rHbA(βL28F), rHbA(βH63Q), and rHbA(βL28Y/βH63Q) were set at 70 °C, 68 °C, and 61 °C, 
respectively, which were 3 °C or lower than their corresponding thermal denaturation 
temperatures. In the case of rHbA(βL28W) mutants, no heat treatment was conducted because 
of significant loss by denaturation. 
The Tm value is the thermal denaturation temperature at which 50% of the protein 
secondary structure unfolds.143 This value was determined from CD spectral changes at 222 
nm α-helices. We prepared carbonyl rHbA(X) ([HbA] = 0.5 μM) in PBS (pH 7.4) in a 10 mm 
optical quartz cuvette sealed with a rubber septum, and CO gas was the flowed in. CD 
spectral data (25–90 °C) at 222 nm was collected by a CD spectrometer (J-820, Jasco Corp.). 
The rate of heating was 1 °C/min and the Tm value was the temperature when α fell below 0.5 
was calculated by: 
Table 4-5. Primers used for construction of rHbA(X) variants (X = βL28F, βL28W, βH63Q, and 
βL28Y/βH63Q) 
Primer name Sequence 
βL28F forward 5’-GATGAAGTGGGTGGTGAAGCATTTGGTCGTCTGCTGGTAGTG-3’ 
βL28F reverse 5’-CACTACCAGCAGACGACCAAATGCTTCACCACCCACTTCATC-3’ 
βL28W forward 5’-GATGAAGTGGGTGGTGAAGCATGGGGTCGTCTGCTGGTAGTG-3’ 
βL28W reverse 5’-CACTACCAGCAGACGACCCCATGCTTCACCACCCACTTCATC-3’ 
βH63Q forward 5’-CCCAAGGTCAAAGCACAAGGGAAGAAAGTCCTGGGCGCG-3’ 
βH63Q reverse 5’-CGCGCCCAGGACTTTCTTCCCTTGTGCTTTGACCTTGGG-3’ 
βL28Y forward 5’-GATGAAGTGGGTGGTGAAGCATACGGTCGTCTGCTGGTAGTG-3’ 
βL28Y reverse 5’-CACTACCAGCAGACGACCGTATGCTTCACCACCCACTTCATC-3’ 
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α = (θt − θU)/( θF − θU), 
where α is the content ratio of the unfolded form, θt is the observed ellipticity at any 
temperature, θF is the ellipticity of the fully folded form (at 25 °C), and θU is the ellipticity of 
the unfolded form at 90 °C.143 
 
O2-Binding Properties of rHbA Variants 
Preparation of the oxy and deoxy forms used the procedure for rHbA(wt). To prepare the oxy 
rHbA(X) variant, O2 gas was flowed to the PBS solution of the carbonyl rHbA(X) ([HbA] = 3 
μM) in a 10 mm optical quartz cuvette sealed with a rubber septum under a 50 W LED lamp 
in an ice-water bath. N2 gas was then flowed continuously and 20 μM sodium dithionite (in 
PBS) was added to the oxy form solution to yield deoxy rHbA(X).The O2-binding properties 
(P50, n) were measured by an automatic recording system for the O2-equilibrium curves 
(Hemox Analyzer) in PBS (pH 7.4) at 37 °C ([HbA] = 10 μM). 
 
4.3 Synthesis of Recombinant Hemoglobin–Albumin Clusters with a 
Mutated Heme Pocket 
4.3.1 Synthesis of rHbA(X)–rHSA3 Cluster Variants 
Preparation of each rHbA(X)–rHSA3 cluster variant was carried out with a method similar to 
that used for rHbA(wt)–rHSA3 clusters (Figure 4-4). SEC profiles of the reaction mixture of 
rHbA(βL28W) or rHbA(βL28Y/βH63Q) suggested that reactivity of surface Lys on the 
rHbA(X) was lower than that of rHbA(wt) (Figure 4-4C). Therefore, we increased the molar 
ratio of rHSA added to rHbA(X) from 4.5-fold to 10-fold for rHbA(βL28W) and 6-fold for 
rHbA(βL28Y/βH63Q), respectively. It is described in detail in the experimental section. 
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Figure 4-4. SEC profiles of the reaction mixture and rHbA(X)–rHSA3 clusters: (A) rHbA(βL28F)–rHSA3 
(red), (B) rHbA(βH63Q)–rHSA3 (orange), and (C) rHbA(βL28Y/βH63Q)–rHSA3 (green). 
 
4.3.2 Experimental Section 
Preparation conditions for the two rHbA(X)–rHSA3 clusters (X = βL28F, βH63Q) were 
identical to that used for rHbA(wt)–rHSA3. However, reactivity of core rHbA(X) (X = 
βL28W and βL28Y/βH63Q) was reduced compared with rHbA(wt), and the molar ratio of 
rHSA was therefore increased. For rHbA(βL28Y/βH63Q)–rHSA3 and rHbA(βL28W)–rHSA3, 
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the additional molar ratio of rHSA to rHbA(X) was increased to 6-fold and 10-fold, 
respectively. 
 
Synthesis of rHbA(βL28Y/βH63Q)–rHSA3 Clusters 
A DMSO solution of SMP (150 mM, 50 μL) was added dropwise to carbonyl 
rHbA(βL28Y/βH63Q) (1 mM, 0.5 mL) in PBS (pH 7.4). After the mixture was stirred for 1 h 
at 4 ºC, unreacted cross-linkers in the reactant were removed using GFC and the 
MA-rHbA(βL28Y/βH63Q) was concentrated to 1.45 mL ([HbA] = 0.35 mM). A PBS solution 
of rHSA (2.85 mM, 1.05 mL) was the added to MA-rHbA(βL28Y/βH63Q) with stirring for 
72 h at 4 ºC ([rHSA]/[rHbA] = 6 mol/mol). 
 
Synthesis of rHbA(βL28W)–rHSA3 Cluster 
A DMSO solution of SMP (150 mM, 50 μL) was added dropwise to carbonyl rHbA(βL28W) 
(1 mM, 0.5 mL) in PBS (pH 7.4). After the mixture was stirred for 1 h at 4 ºC, unreacted 
cross-linkers in the reactant were removed using a centrifugal filter (Amicon Ultra 15, 10 kDa 
MWCO; Merck Millipore Ltd.). The MA-rHbA(βL28W) was adjusted to 1.246 mL ([HbA] = 
0.4 mM). A PBS solution of rHSA (2.85 mM, 1.754 mL) was the added to 
MA-rHbA(βL28W) with stirring for 72 h at 4 ºC ([rHSA]/[rHbA] = 10 [mol/mol]). 
 
4.4 O2-Binding Property of Recombinant Hemoglobin–Albumin Clusters 
with a Mutated Heme Pocket 
4.4.1 O2-Binding Property of Recombinant Hemoglobin–Albumin Cluster with a 
Mutated Heme Pocket 
The maximum absorption wavelengths in oxy, deoxy, and carbonyl forms of rHbA(X)–rHSA3 
cluster variants exhibited values almost equal to those of naked rHbA(X) (Table 4-6). 
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The O2-binding parameters (P50, n) of rHbA(X)–rHSA3 cluster variants indicated a 
reducing tendency similar to that of wild-type clusters. The P50 and n values of 
rHbA(βH63Q)–rHSA3 were found to be 8 Torr and 1.4, respectively, which were identical to 
wild-type cluster values (Table 4-7). The P50 values of rHbA(X)–rHSA3 clusters (X = βL28F, 
βL28W, and βL28Y/βH63Q), were 14 Torr, 24 Torr, and 15 Torr, respectively. 
 
 
 
 
 
 
The rHbA(X)–rHSA3 cluster variants showed a lower P50 and Hill coefficient (n) 
compared with naked rHbA(X). The reductions can be attributed to the chemical 
modifications of the carbonyl rHbA(X) by cross-linkers, as in the case of HbBv–HSA3 
clusters. First, the chemical modification of surface Lys on carbonyl rHbA(X) fixed the 
quaternary structure in the R-state (high O2 affinity). Second, the masking of Cys-β93 in 
rHbA by the maleimide group of SMP inhibited quaternary structural conversion between the 
R and T state. However, the O2 affinity of rHbA(X)–rHSA3 clusters was lower than that of the 
wild-type cluster. This suggests that replacing the Leu-β28 reduced the O2 affinity of the 
Table 4-6. Visible absorption spectral data of rHbA(X)–rHSA3 cluster variants in PBS solution (pH 
7.4) at 25 °C 
Hemoprotein 
λmax (nm) 
oxy deoxy carbonyl 
rHbA(βL28F)–rHSA3 415, 541, 577 430, 556 420, 539, 569 
rHbA(βL28W)–rHSA3 414, 541, 576 430, 556 419, 538, 569 
rHbA(βH63Q)–rHSA3 415, 541, 576 430, 556 420, 539, 569 
rHbA(βL28Y/βH63Q)–rHSA3 413, 540, 576 430, 556 420, 539, 569 
Table 4-7. The O2-binding parameters of rHbA(X)–rHSA3 cluster variants in PBS 
solution (pH 7.4) at 37 °C 
Hemoglobin P50 (Torr) n (–) kox (h−1) 
rHbA(βL28F)–rHSA3 14 1.2 0.130 
rHbA(βL28W)–rHSA3 24 1.0 0.082 
rHbA(βH63Q)–rHSA3 8 1.4 0.040 
rHbA(βL28Y/βH63Q)–rHSA3 15 1.1 0.115 
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rHbA(X) β-globin in the R-state. 
The P50 values of the rHbA(X)s (X = βL28F, βL28W, and βL28Y/βH63Q) and their 
clusters showed a liner dependence on the increment of the side group volume at the β28 
position (Figure 4-5).144 Suppression of T-R structural alterations in core rHbA induced by 
SMP modification reduced the slope of the clusters relative to that of naked rHbA(X)s. 
 
 
 
 
 
 
 
 
Figure 4-5. Dependence of P50 values on the β28 position side-chain volume.144 The circle symbol denotes 
rHbA(X), the triangle symbol respresents the rHbA(X)–rHSA3 cluster. rHbA(wt): black; rHbA(βL28F): 
red; rHbA(βL28W): blue; and rHbA(βL28Y/βH63Q): green. 
 
4.4.2 Experimental section 
To prepare oxy forms, O2 gas was flowed to the PBS solution of the carbonyl rHbA(X)–
rHSA3 cluster ([HbA unit] = 10 μM, 3 mL) in a 10 mm optical quartz cuvette sealed with a 
rubber septum under an LED lamp in an ice-water bath. N2 gas was then flowed continuously 
and 20 μM sodium dithionite was added to the oxy form solution to yield deoxy an rHbA(X)–
rHSA3 cluster. The autoxidation rate constant (kox) of the rHbA(X)–rHSA3 cluster was 
determined from absorption intensity at 630 nm with time in aerobic conditions a 37 °C, 
which was based on metHb formation. O2-binding parameters (P50, n) were determined by a 
Hemox Analyzer in PBS (pH 7.4) at 37 °C. 
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4.5 Conclusion 
We prepared 4 rHbA(X) variants in which the β-globin heme pocket was mutated by 
site-directed mutagenesis. The O2 affinity of rHbA(X)–rHSA3 clusters (X = βL28F, βL28W, 
and βL28Y/βH63Q) was moderately higher (as measured by P50 value) than that of 
rHbA(wt)–rHSA3 clusters. By replacing the Leu-β28 position of core Hb with bulky amino 
acid residues, we tuned the O2 affinity of the cluster. The P50 values of these clusters exhibited 
linear dependence on the side-chain volume at the β28 position. In particular, the P50 value of 
rHbA(βL28W)–rHSA3 clusters was 24 Torr, which was almost identical to the RBC value. 
The estimated O2-transporting efficiency of rHbA(βL28W)–rHSA3 cluster between lungs 
(100 Torr) and muscles (40 Torr) was also the same as that of RBC (18%). We expect that 
various rHbA(X)–rHSA3 clusters with different O2 affinities could be used for diverse clinical 
applications.  
74 
 
 
 
 
 
 
Chapter 5 
 
Evaluations of Hemoglobin–Albumin Cluster by 
Animal Experiments  
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5.1 Introduction 
By establishing large-scale preparation of HbBv–HSA3 clusters, it was possible to evaluate 
safety and efficacy by exchange transfusion145 and brain neuroprotection from 
ischemia/reperfusion injury.146,147 This chapter describes the physiological responses after 
20% exchange transfusion in anesthetized rats and blood-circulation persistence in dogs with 
an HbBv–HSA3 cluster. In the case of 20% exchange transfusion in rats, 4 mL of an HbBv–
HSA3 cluster formulation ([HbBv unit] = 5 g/dL) is required at one time. In the experiments 
using dogs, the required volume of HbBv–HSA3 cluster formulation is 1.8 mL for 
measurement of blood-circulation time, and 18 mL for anti-HSA antibody measurements in 
blood plasma. 
 
5.2 Safety Evaluation of Hemoglobin–Albumin Cluster by 20% Exchange 
Transfusion 
5.2.1 Blood Compatibility of HbBv–HSA3 Clusters with Human Blood in vitro 
Human blood was mixed with HbBv–HSA3 cluster formulation ([HbBv unit] = 5 g/dL), and 
the blood, including RBC, white blood cell (WBC), and platelet (PLT) components, in a 
homogeneous suspension were quantified. The basal values (BVs) of the blood components 
were 457 ± 12 × 104 cells/μL in RBCs, 43 ± 4 × 102 cells/μL in WBCs, and 24 ± 1 × 104 
cells/μL in PLTs, respectively. The RBC, WBC, and PLT quantities decreased depending on 
the HbBv–HSA3 cluster volume ratio: ca. 90, 80, and 60% of the baseline value, respectively, 
in 10, 20, and 40 vol% HbBv–HSA3 cluster samples (Figure 5-1A). These results were the 
same as those observed in the HSA groups (Figure 5-1B). 
The influence of HbBv–HSA3 clusters on blood coagulation was evaluated by 
prothrombin time (PT) assays, which estimated the extrinsic and common pathways of 
coagulation cascades.148,149 After centrifugation of the blood/HbBv–HSA3 mixture, the plasma 
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phase turned pale red in the presence of HbBv–HSA3 clusters. The dilution of blood generally 
caused a decrease in the amount of thrombin, prolonging coagulation time. The PT values 
increased slightly depending on the HbBv–HSA3 cluster volume ratio (10, 20, and 40 vol%) 
(Figure 5-1C). The results were identical to those observed in the PBS and HSA groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1. Blood compatibility of HbBv–HSA3 clusters with human blood. (A) Blood cell component 
(RBC, WBC, and PLT) numbers in a human blood/HbBv–HSA3 mixture suspension ([HbBv–HSA3] = 10, 
20, and 40 vol%) (n = 3). BVs were 457 ± 12 × 104 cells/μL in the RBC group, 43 ± 4 × 102 cells/μL in the 
WBC group, and 24 ± 1 × 104 cells/μL in the PLT group. (B) Blood cell numbers in the human blood/HSA 
mixture suspension (n = 3). BVs were 458 ± 11 × 104 cells/μL in the RBC group, 43 ± 4 × 102 cells/μL in 
the WBC group, and 24 ± 1 × 104 cells/μL in the PLT group. (C) PT values of human blood samples after 
mixing with HbBv–HSA3 clusters, HSA, and PBS solution (10, 20, and 40 vol%) (n = 3). 
 
5.2.2 Circulation and Blood-Gas Parameters in Rats 
Results of the 20% exchange transfusion test in rats showed that all animals in the HbBv–
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HSA3 cluster group were alive during the experimental period (6 h) (Figure 5-2) and no 
remarkable changes in appearance were noted. The hematocrit (Hct) value decreased rapidly 
by blood replacement from 36.9% to 28.7%, and the values were then constant for 6 h (Figure 
5-2A). A similar change was observed in the HSA group. The Hct of the sham (without 
replacement) group remained constant through the end of measurements. The time courses of 
mean arterial pressure (MAP) in the HbBv–HSA3 cluster group showed only a small 
deviations of 98–112 mmHg (Figure 5-2B). No hypertensive action was observed after 
hemodilution with the HbBv–HSA3 cluster group. In the sham and HSA groups, the changes 
in MAP were almost identical to those of the HbBv–HSA3 cluster group. The heart rate (HR) 
and respiration rates (RESP) of animals in each group did not change during monitoring 
(Figure 5-2C, D). The body temperatures of the sham, HSA, and HbBv–HSA3 animals 
remained stable between 36.7 and 37.1 °C during the experiment (6 h) (Figure 5-2E). 
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Figure 5-2. Changes in the circulation parameter. Time causes of circulation parameters of anesthetized rats 
after 20% exchange transfusion with HbBv–HSA3 cluster HSA solution: (A) Hct, (B) MAP, (C) HR, (D) 
RESP, and (E) body temperature. Each datum represents mean ± standard error (n = 3). *p < 0.05 vs. sham 
group, **p < 0.01 vs. sham group. 
 
The O2 partial pressures in arterial blood (PaO2) of the sham, HSA, and HbBv–HSA3 
cluster groups were constant in a range of 112–145 mmHg by the end of the experimental 
period (6 h) (Figure 5-3A). The O2 partial pressures in venous blood (PvO2) of each group 
also exhibited small changes within 41–59 mmHg (Figure 5-3B). No significant difference in 
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the PaCO2, pH, and HCO3− was found in the sham, HSA or HbBv–HSA3 cluster group during 
the observation term (Figure 5-3C, D, E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Changes of blood-gas parameters. Time causes of blood-gas parameters of anesthetized rats 
after 20% exchange transfusion with HbBv–HSA3 cluster HSA solution: (A) PaO2, (B) PvO2, (C) PaCO2, 
(D) pH, and (E) HCO3−. Each datum represents mean ± standard error (n = 3). *p < 0.05 vs. sham group, 
**p < 0.01 vs. sham group. 
 
5.2.3 Measurement of Blood-Circulation Lifetime of HbBv–HSA3 Cluster in Dogs 
First, we confirmed the compatibility of HbBv–HSA3 clusters with canine blood. The blood 
cell components after mixing with HbBv–HSA3 clusters were then counted. The quantities of 
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RBCs, WBCs, and PLTs decreased in relation to the HbBv–HSA3 cluster volume ratio (Figure 
5-4A). These results were also recorded in the HSA groups (Figure 5-4B). The influence of 
HbBv–HSA3 clusters on blood coagulation was also evaluated by determination of PT. The 
PT values increased slightly depending on HbBv–HSA3 cluster volume ratio, at 10, 20, and 40 
vol% (Figure 5-4C), because the amount of thrombin fell with blood dilution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4. Blood compatibility with canine blood. (A) Blood cell (RBC, WBC, and PLT) numbers in 
canine blood/HbBv–HSA3 mixture suspension ([HbBv–HSA3] = 10, 20, 40 vol%). BVs were 801 ± 14 × 
104 cells/μL in the RBC group, 94 ± 5 × 102 cells/μL in the WBC group, and 39 ±1 × 104 cells/μL in the 
PLT group. Each datum represents mean ± SEM (n = 3). (B) Blood cell numbers in canine blood/HSA 
mixture suspension ([HSA] = 10, 20, 40 vol%). BVs were 810 ± 17 × 104 cells/μL in the RBC group, 99 ± 
5 × 102 cells/μL in the WBC group, and 40 ± 1 × 104 cells/μL in the PLT group. Each datum represents 
mean ± SEM (n = 3). (C) PT values of canine blood samples after mixing with HbBv–HSA3 clusters and 
HSA solution (10, 20, 40 vol%). Each datum represents mean ± SEM (n = 3). 
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Next, we measured the retention time of HbBv–HSA3 clusters in dog blood-circulation 
using a fluorescence reagent, a Cyanine 5.5–bound derivative (HbBv–HSA3[Cy5.5]). The 
binding number of Cy5.5 on HbBv–HSA3 clusters was 3.2. The fluorescence intensity of 
HbBv–HSA3(Cy5.5) clusters in human plasma was stable over 48 h at 37 °C in vitro, whereas 
gradual breeching was observed in PBS (Figure 5-5). Cy5.5 labeling did not alter the charge 
and size of HbBv–HSA3 clusters (pI: 5.0, diameter: 15 nm).19,150 
 
 
 
 
 
 
 
 
Figure 5-5. Fluorescence stability of HbBv–HSA3(Cy5.5). Time courses of fluorescence intensities of 
HbBv–HSA3(Cy5.5) (λem = 707 nm) in human plasma and PBS at 37 °C. 
 
We inferred that the HbBv–HSA3(Cy5.5) cluster was useful as a fluorescence probe to 
investigate the pharmacokinetics, distribution, and metabolism of HbBv–HSA3 cluster. A test 
sample (HbBv–HSA3/HbBv–HSA3[Cy5.5] = 9/1 vol/vol) was injected intravenously to dogs 
via a jugular vein. For pharmacokinetic experiments of artificial O2-carriers, a dose of more 
than 10 % of the total blood volume is generally desirable. However, pure dynamics of 
HbBv–HSA3 cluster cannot be assessed under such conditions, because the metabolism and 
excretion system of HbBv–HSA3 clusters may be saturated. Instead, we injected 1% of the 
total blood volume, which does not saturate the metabolism and excretion system. The time 
course of the relative plasma concentration of HbBv–HSA3(Cy5.5) showed slow kinetics in a 
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biphasic manner. The blood-circulation half-time (τ50) of the HbBv–HSA3 cluster was 46.9 ± 
1.9 h (Figure 5-6). The negative net surface charge and large molecular size of HbBv–HSA3 
clusters prevented not only extravasation through the vascular endothelium, but also filtration 
by the renal glomerulus. 
 
 
Figure 5-6. Circular lifetime. Relative plasma concentration of HbBv–HSA3(Cy5.5) in dogs after 
intravenous administration. Each datum represents mean ± SEM (n = 5). 
 
5.2.4 Test of Anti-HSA Antibody Generation in Blood Plasma 
To observe the immunological response, the HbBv–HSA3 cluster was injected into a beagle 
dog at a dose of 10% of total blood volume. The number of antibodies against HSA in canine 
plasma increased 14 days after the injection and remained constant during monitoring (35 
days) (Figure 5-7). Administration of HSA generated significant numbers of anti-HSA 
antibodies: 2.3 to 2.9 times that of the HbBv–HSA3 cluster. 
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Figure 5-7. Generation of anti-HSA antibodies in canine plasma. Time courses of differential absorption 
(A405−A490) of the specimen, which are proportional to concentration of anti-HSA antibody in blood plasma 
after intravenous administration of HbBv–HSA3 cluster and HSA solution in dogs. The dose rate was 10% 
of total blood volume. BI: just before infusion, 0: immediately after infusion. 
 
5.2.6 Experimental Section 
Materials and Apparatus 
HSA was purchased from the Japan Blood Products Organization (Tokyo, Japan) and purified 
using GFC to remove stabilizing reagents such as N-acetyl-tryptophan and octanoate 
(caprylate). For exchange transfusion, a PBS (pH 7.4) solution of HSA was used. The 
concentration of HbBv units in HbBv–HSA3 cluster formulation was 5 g/dL in PBS. A 
fluorescence-labeling reagent, Cyanine5.5 (Cy5.5) N-hydroxysuccinimide ester, was 
purchased from Lumiprobe Corp. (Maryland, USA). All other chemical reagents were 
purchased from commercial sources as special grades and were used without further 
purification. UV-visible absorption spectra were measured using a UV-visible spectrometer 
(8543; Agilent technologies Inc.) with an attached Peltier temperature controller (89090A; 
Agilent Technologies Inc.) Fluorescence emission spectra were recorded using a 
spectrofluorometer (FP-6500; Jasco Corp.). The molecular size was determined by DLS 
measurements using a particle-size analyzer (ELSZ-200; Otsuka Electronics Co., Ltd.). 
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Preparation of Cy5.5-Labeled HbBv–HSA3 Clusters 
A DMSO solution of Cy5.5 N-hydroxysuccinimide ester (12 mM, 80.4 μL) was added to a 0.1 
M NaHCO3 solution (pH 8.4) of HbBv–HSA3 clusters ([HbBv unit] = 150 μM, 724 μL) 
([Cy5.5]/[HSA] = 8 mol/mol), and stirred in the dark for 24 h at 25 °C. The obtained reaction 
mixture was subjected to GFC (Sephadex G-25 superfine; GE Healthcare UK Ltd.) to remove 
unreacted Cy5.5 with PBS as a running buffer. The eluent was concentrated to 156 μL ([HbBv 
unit] = 5 g/dL, 775 μM) using a centrifugal filter (Amicon Ultra 15, 30 kDa MWCO; Merck 
Millipore Ltd.). After CO gas was flowed into HbBv–HSA3(Cy5.5) to prevent core Hb 
oxidation, the UV-visible absorption spectrum was used to measure the Cy5.5/HbBv–HSA3 
molar ratio. From the absorbance of HbBv–HSA3(Cy5.5) at 420 nm (based on carbonyl core 
Hb) and at 684 nm (based on Cy5.5), HbBv units and Cy5.5 were assayed using their molar 
extinction coefficients (carbonyl Hb: ε420 = 7.64 × 105 M−1 cm−1, Cy5.5: ε684 = 2.09 ×105 M−1 
cm−1). The Cy5.5/HbBv–HSA3 ratio was 3.2. 
 
Blood Compatibility of HbBv–HSA3 Clusters with Human Blood in vitro 
Human blood was withdrawn from the authors and stored in a blood collection tube (Venoject 
II, EDTA-2Na; Terumo Corp.). HbBv–HSA3 cluster formulation was then added to the blood 
([HbBv–HSA3] = 0, 10, 20, and 40%, total volume = 1.0 mL each) in a plastic microtube, and 
individual samples were mixed by inverting. The blood cell number of each sample was 
measured using an automated hematology analyzer (pocH-100iV Diff; Sysmex Corp.). The 
results are represented as percent ratios against the blood cell numbers of samples without 
dilution (0 vol% HbBv–HSA3). As control groups, blood suspensions mixed with HSA (15 
g/dL) ([HSA] = 10, 20, and 40 vol%) were also measured. Data are shown as mean ± standard 
error of the mean (SEM) (n = 3). Human blood was withdrawn from the authors into a 
vacuum blood collection tube (Neotube, 3.2% sodium citrate; Nipro Corp.). After HbBv–
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HSA3 cluster formulation was added to the blood ([HbBv–HSA3] = 0, 10, 20, and 40 vol%, 
total volume = 1.2 mL each) in a plastic microtube, the individual samples were mixed by 
inverting. These samples were centrifuged (2800 g) for 15 min at 4 °C. The supernatant (0.6 
mL) was immediately transferred to a separation tube (S-1; BML Inc.) and frozen at −80 °C. 
The determination of PT was conducted by BML Inc. (Tokyo, Japan). As control groups, 
blood suspensions diluted with HSA (15 g/dL) or PBS (10, 20, and 40%) were also measured. 
Data are shown as mean ± SEM (n = 3). 
 
Circulation Parameters and Blood-Gas Parameters in Rats 
Nine male Wister rats (277 ± 10 g) were placed on a heating pad under an inhalation 
anesthesia with sevoflurane (3.0–4.0% concentration). After an incision was made in the 
digastric muscle, a heparinized catheter (SP-31; Natsume Seisakusho Co. Ltd.) was 
introduced into the right common carotid artery for blood withdrawal and continuous MAP 
monitoring (A-line). SP-31 catheters were inserted approximately 2 cm into the left jugular 
vein for sample injection (V-line). After stabilization of the animal condition, the 20% 
exchange transfusion (total blood volume of rat estimated as 56 mL/kg weight) was 
conducted by 1 mL blood withdrawal via the A-line and 1 mL HbBv–HSA3 infusion via the 
V-line (each 1 mL/min) with 3 repeating cycles (HbBv–HSA3 group, n = 3). Blood samples 
were taken from the A-line (0.3 mL) and V-line (0.2 mL) at the following 5 time-points: 
before exchange transfusion and 0 (immediately after), 1, 3, and 6 h after exchange 
transfusion. Simultaneously, MAP and HR were recorded using an invasive blood pressure 
measurement system (BPM100-PC; Star Medical Inc.). The blood sample was dropped 
rapidly on a test cartridge (i-STAT test cartridge CG4+; Abbot Point of Care Inc.) to measure 
O2 partial pressure (PaO2), CO2 partial pressure (PaCO2), pH, and HCO3− for the arterial 
blood, and O2 partial pressure for the venous blood (PvO2). Furthermore, the Hct value was 
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measured using a heparinized Hct capillary (C-H075H; Terumo Corp.). After 6 h, 4 mL of the 
arterial blood was withdrawn from the A-line using a non-treated syringe before sacrifice by 
hemorrhage. The blood samples were transferred into a vacuum blood collection tube 
(Venoject II) and centrifuged at 4000 g and 4 °C for 15 min. The plasma phase was 
transferred to a separation tube (S-1; BML Inc.) and frozen at −80 °C for serum biochemical 
tests. Other rats without infusion (operation only) were set as a sham group (n = 3). 
 
Measurement of Blood-Circulation Lifetime of HbBv–HSA3 Clusters in Dogs 
First of all, we evaluated the chemical stability of HbBv–HSA3(Cy5.5) in vitro. The HbBv–
HSA3(Cy5.5) solution (1 mM) in human plasma, which was derived from the blood of the 
author, or in PBS solution was incubated at 37 °C, subsequently fluorescence spectrum was 
measured for 48 h. Next, animal experiments were conducted with 5 male beagle dogs (~2 kg, 
n = 5). The gender difference of the dogs was small compared with the rats, but we used male 
dogs to be safe. The test sample (non-labeled HbBv–HSA3/ HbBv–HSA3[Cy5.5] = 9/1 
[vol/vol], 1.8 mL), which corresponded to 1% of the total blood volume of the dog (90 mL/kg 
weight), was injected intravenously via the jugular vein without anesthesia. Blood samples 
were then taken from the jugular vein (2.0 mL) using a non-treated syringe at the following 9 
time-points: 0 (immediately after injection) and 1, 2, 5, 24, 30, 48, 54, and 72 h after injection. 
The Hct value was measured using a heparinized Hct capillary. After Hct measurements, the 
remaining blood was transferred into a blood collection tube (NP-SP0715; Nipro Corp.) and 
centrifuged (2800 g) for 15 min at 4 °C to remove blood cell components. The supernatant 
(0.5 mL) was moved into a plastic microtube and stored at 4 °C in the dark. The fluorescence 
spectrum of each sample was then measured (λex = 684 nm, λem = 707 nm). The relative 
plasma concentration of HbBv–HSA3(Cy5.5) (C) was found using the equation 
C = (F / F0) × 100 (%), 
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where F is fluorescence intensity of the supernatant at each time-point and F0 signifies the 
fluorescence intensity of the supernatant immediately after the infusion. The blood-circulation 
half-time (τ50) was ascertained using Moment analysis. 
 
Test of Anti-HSA Antibody Generation in Blood Plasma 
Experiments were performed with 3 male beagle dogs (~2 kg). The HbBv–HSA3 cluster 
solution (18 mL), which corresponded to 10% of the total blood volume of the dog, was 
injected intravenously via the femoral vein under a sedation with medetomidine 
hydrochloride. Then blood samples were taken from the jugular vein (2.0 mL) using a 
non-treated syringe at 8 time-points: before infusion and 0 (immediately after infusion), 1, 7, 
14, 21, 27, and 35 days after infusion. The blood sample was transferred into a blood 
collection tube and centrifuged (2800 g) for 15 min at 4 °C to remove the blood cell 
components. The supernatant was then moved into the separation tube and was frozen at 
−80 °C. An anti-HSA antibody assay was performed by an enzyme-linked immunosorbent 
assay method using an alkaline phosphatase-labeled rabbit anti-dog immunoglobin G antibody. 
Alkaline phosphatase activity was determined colorimetrically by adding p-nitrophenyl 
phosphate disodium salt (Merk KGaA) as a substrate. The absorbance of the resulting product 
was measured at 405 nm (product) and 490 nm (background). As a control, the HSA solution 
(15 g/dL) was administrated to a beagle dog. Another beagle without infusion (operation only) 
was used as a sham. At 35 days from the infusion, the beagles were sacrificed by 
exsanguination. 
 
5.3 Conclusion 
Dilution of human blood with 10–40 vol% HbBv–HSA3 clusters showed appropriate 
decreases in RBC, WBC, and PLT numbers. The coagulation function of the blood was 
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maintained in the presence of HbBv–HSA3 clusters. No physicochemical interaction was 
observed between HbBv–HSA3 clusters and the human blood cell components. Replacing 
20% of blood with the HbBv–HSA3 cluster solution produced no acute toxicity or negative 
side effects in the rats. The physiological responses in blood-circulation and gas equilibria in 
the HbBv–HSA3 cluster group were almost identical to those of the sham and HSA groups. 
Moreover, MAP and HR remained constant for 6 h, implying that HbBv–HSA3 clusters do not 
engender vasoconstrictive effects. The fluorescent HbBv–HSA3(Cy5.5) allowed us to measure 
the blood-circulation time in dogs using a fluorescence spectrometer. The nonvasopressor 
response and superior blood retention property of HbBv–HSA3 can be attributed to the 
negative net surface charge and larger molecular size of the clusters. All results from this 
study indicate the preclinical safety of the HbBv–HSA3 solution, which allows us to conduct 
further advanced preclinical testing of this protein cluster as a new class of RBC substitutes. 
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Chapter 6 
 
Conclusions and Future Prospects  
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Conclusions 
The final goal of the study was the practical application of the Hb–HSA3 cluster as an RBC 
substitute. As a first step, enlargement of the synthetic scale of Hb–HSA3 cluster is required. 
In this thesis, the author demonstrated efficient preparation procedures that can be expanded 
to a scale of several tens of liters. First, the cross-linker was changed to a water soluble 
derivative, SMP. We can synthesize HbBv–HSA3 without side reactions even at a high Hb 
concentration (1 mM, 65 g/L). This improvement shortened the reaction time and increased 
reaction efficiency. Second, the author established a purification procedure using AEC. 
Reproducibility and separation efficiency of HbBv–HSA3 clusters increased significantly 
compared with conventional GFC. These two improvements allowed us to prepare 74 mL of 
an HbBv–HSA3 cluster formulation ([HbBv unit] = 5 g/dL) at one time, which is 
approximately 20-fold greater than is possible using the conventional method. Chromogenic 
LAL assay of LPS in the HbBv–HSA3 cluster formulation was also conducted. We found that 
adding disaccharide, sucrose, and trehalose to the HbBv–HSA3 cluster formulation allowed 
for lyophilization without protein denaturing. The lyophilized HbBv–HSA3 cluster powder 
could be stored for 2 years. 
As a second step, we expressed and purified recombinant HbA [rHbA(wt)], which can be 
used as raw material for the cluster. An rHbA(wt) expression strain was constructed by 
transforming a methylotrophic yeast, P. pastoris. The structure and O2-binding property of 
rHbA(wt) were identical to those of native HbA, as revealed by MALDI-TOF mass 
spectroscopy, X-ray crystal analysis, and O2-dissociation curve measurements. This is the first 
example of rHbA expressed in P. pastoris as a host cell. Moreover, rHbA(wt)–rHSA3 clusters 
showed the same O2-binding property as that of HbA–HSA3 cluster. The rHbA(wt)–rHSA3 
cluster is an entirely synthetic artificial O2-carrier that requires no donated blood as raw 
materials. 
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Subsequently, the author revealed that the O2 affinity of rHbA(X)–rHSA3 clusters can be 
modulated through mutations of distal amino acid residues in the core Hb. We prepared 3 
rHbA(X) variants in which Leu-β28 was replaced with a bulky amino acid (Phe, Tyr, or Trp). 
All rHbA(X)–rHSA3 cluster variants showed lower O2 affinity compared with rHbA(wt)–
rHSA3 clusters. In particular, the P50 value of rHbA(βL28W)–rHSA3 cluster was 24 Torr, 
which was almost identical to that of human RBCs. This suggests that genetically engineered 
rHbA(X)–rHSA3 clusters can become not only a promising RBC substitute but also an O2 
therapeutic reagent. 
Finally, the author evaluated the safety and efficacy of the HbBv–HSA3 cluster 
formulation as an RBC substitute by animal experiments. 
All these results demonstrated that HbBv–HSA3 and rHbA(X)–rHSA3 clusters can be of 
great medical importance, not only as RBC substitutes, but also as O2 therapeutic reagents in 
various clinical situations. 
 
Future Prospects 
The author believes that Hb–HSA3 cluster formulation is a promising RBC substitute for 
current HBOCs because the cluster can not only transport O2 but also provide cytoprotective 
effects by HSA. The adverse effects of organ injury caused by free heme remain problematic 
for PEGylated Hb formulation. The combination of Hb and HSA is important, because HSA 
can capture free heme and may suppress adverse effects. Moreover, it is difficult to 
administrate the cluster formulation at Hb concentrations over 5 g/dL, because of the viscosity 
limits. Furthermore, the low cooperatively (n) of Hb–HSA3 clusters leads to low 
O2-transporting efficiency compared with that of human RBCs. In this thesis, the author 
synthesized rHbA(βL28W)–rHSA3 clusters with the same O2-transporting efficiency as 
human RBCs. 
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If HbA and HSA are produced as a genetically connected fusion protein, rHbA–HSAx, a 
novel artificial O2-carrier with high cooperativity can be synthesized. Some examples of 
fusion protein with HSA are known, such as insulin (Blondel et al., 2005)151 and interferon 
(Zhou et al., 2007)152, for expanding the blood-circulation lifetime. According to a report on 
HSA subdomain I conjugation (Patterson and Rader et al., 2016)153, molecular weight per 
transported O2 molecule will improve. 
Finally, HSA has a secretory signal sequence at the N-terminus. If rHbA–HSAx, in which 
HSA is located at the N-terminus of Hb, can be constructed as a secretory system, the yield 
will reach to several g/dL, making it a promising, and profitable, artificial O2-carrier.  
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